FLASCO

FLASCO News

Home » Current News & Publications » FLASCO News

“Love” Rocks Bring Hope to Local Cancer Patients in Wellington

Posted July 20, 2017

Brought to you by a 100% FLASCO Membership Partner Wellington, FL – July 19, 2017…The Florida Cancer Specialists Foundation, in conjunction with the local Florida Cancer Specialists (FCS) clinic in Wellington, FL, received 200 “Go and Love” rocks from local congregation, Journey Church. The initiative recently launched by Journey Church’s student ministry aims to spread “rocks”...

CMS Releases Proposed Medicare Payment Rules for 2018

Posted July 20, 2017

The Centers for Medicare and Medicaid Services (CMS) has issued two proposed rules to update payment policies and payment rates for services furnished under the Medicare Physician Fee Schedule (PFS) and the Hospital Outpatient Prospective Payment System (OPPS). CMS will be accepting comments on these rules until September 11, 2017. The final rules are expected...

FDA Clears Puma Biotechnology’s Nerlynx for Extended Adjuvant Treatment of HER2-positive Early-Stage Breast Cancer

Posted July 20, 2017

On July 17, 2017, the U.S. Food and Drug Administration approved neratinib (NERLYNX, Puma Biotechnology, Inc.) for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, to follow adjuvant trastuzumab-based therapy. Approval was based on the ExteNET trial (NCT00878709), a multicenter, randomized, double-blind, placebo-controlled trial of neratinib following adjuvant trastuzumab treatment....

FDA Approved

FDA Approves New Drug to Treat Adults with Chronic Hepatitis C Virus genotypes 1-6 without Cirrhosis or with Mild irrhosis

Posted July 20, 2017

The U.S. Food and Drug Administration today approved Vosevi to treat adults with chronic hepatitis C virus (HCV) genotypes 1-6 without cirrhosis (liver disease) or with mild cirrhosis. Vosevi is a fixed-dose, combination tablet containing two previously approved drugs – sofosbuvir and velpatasvir – and a new drug, voxilaprevir. Vosevi is the first treatment approved...

FDA Approves New Treatment for Sickle Cell Disease

Posted July 13, 2017

The U.S. Food and Drug Administration today approved Endari (L-glutamine oral powder) for patients age five years and older with sickle cell disease to reduce severe complications associated with the blood disorder. “Endari is the first treatment approved for patients with sickle cell disease in almost 20 years,” said Richard Pazdur, M.D., acting director of...

FDA Grants Full Approval for BLINCYTO® (blinatumomab) to Treat Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia in Adults and Children

Posted July 13, 2017

Amgen announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for BLINCYTO® (blinatumomab) to include overall survival (OS) data from the Phase 3 TOWER study. The approval converts BLINCYTO’s accelerated approval to a full approval. The sBLA approval also included data from the Phase 2 ALCANTARA study...

Information from Merck about EMEND® – Availability of a New NDC

Posted July 10, 2017

Merck has received FDA approval for a new formulation of EMEND for injection that has a lower concentration of edetate disodium (EDTA), an inactive ingredient.  This new formulation (5.4 mg EDTA, NDC 0006-3061-00) will replace the existing formulation (18.8 mg EDTA, NDC 0006-3941-32).  The purpose of this formulation change is to support ongoing regulatory activities...

FDA allows marketing of test to aid in the detection of certain leukemias and lymphomas

Posted July 6, 2017

The U.S. Food and Drug Administration today allowed marketing of ClearLLab Reagents (T1, T2, B1, B2, M), the first agency authorized test for use with flow cytometry to aid in the detection of several leukemias and lymphomas, including chronic leukemia, acute leukemia, non-Hodgkin lymphoma, myeloma, myelodysplastic syndrome (MDS) and myeloproliferative neoplasms (MPN). “This represents a...

FDA clears expanded use of cooling cap to reduce hair loss during chemotherapy

Posted July 6, 2017

The U.S. Food and Drug Administration cleared the expanded use of a cooling cap, DigniCap Cooling System, to reduce hair loss (alopecia) during chemotherapy. This is the first cooling cap cleared by the agency for use in cancer patients with solid tumors. “We are pleased to expand the use of this product for cancer patients...

FDA granted marketing approval to the Praxis Extended RAS Panel

Posted July 6, 2017

On June 29, 2017, the U.S. Food and Drug Administration granted marketing approval to the Praxis Extended RAS Panel (Illumina, Inc.), a next generation sequencing (NGS) test to detect certain genetic mutations in RAS genes in tumor samples of patients with metastatic colorectal cancer (mCRC). The test is used to aid in the identification of...

Dr. Augusto Villegas Joins Florida Cancer Specialists & Research Institute at New Fleming Island Location

Posted June 30, 2017

Brought to you by a 100% FLASCO Membership Partner Nation’s Largest Independent Oncology Group Welcomes New Physician in Jacksonville/Fleming Island Fleming Island, FL – July 3, 2017. . . Florida Cancer Specialists & Research Institute (FCS), the leading community oncology/hematology practice in Florida, is pleased to announce that Augusto E. Villegas, MD has joined the...

teva oncology

Celltrion and Teva Announce U.S. FDA Acceptance of Biologics License Application for Proposed Biosimilar to Rituxan® (rituximab)

Posted June 29, 2017

INCHEON, South Korea & JERUSALEM–(BUSINESS WIRE)–Jun. 29, 2017– Celltrion, Inc., a global biopharmaceutical company, and Teva Pharmaceutical Industries Ltd.(NYSE and TASE: TEVA) today announced that the U.S. Food and Drug Administration(FDA) has accepted for review the Biologics License Application (BLA) for CT-P10, a proposed Monoclonal Antibody (mAb) biosimilar to Rituxan®1 (rituximab), which is used to...

Genentech Announces the FDA Approval of RITUXAN HYCELA for FL, DLBCL, and CLL

Posted June 29, 2017

Indications RITUXAN HYCELA™ (rituximab/hyaluronidase human) is indicated for the treatment of adult patients with: Relapsed or refractory, follicular lymphoma (FL) as a single agent Previously untreated follicular lymphoma in combination with first-line chemotherapy and, in patients achieving a complete or partial response to rituximab in combination with chemotherapy, as single-agent maintenance therapy Non-progressing (including stable...

A select guideline for neoadjuvant treatment of patients with HER2+ early-stage breast cancer

Posted June 28, 2017

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) recommend a pertuzumab (PERJETA®) and trastuzumab (Herceptin®) combination-based neoadjuvant regimen as an option for the treatment of HER2-positive (HER2+) early-stage breast cancer (category 2A)1 Based upon lower-level evidence, there is uniform National Comprehensive Cancer Network® (NCCN®) consensus that the intervention is appropriate (category 2A)1 Could your patients with...

FDA Approves RITUXAN HYCELA for Subcutaneous Injection in Certain Blood Cancers

Posted June 23, 2017

The FDA approved RITUXAN HYCELA™ (rituximab and hyaluronidase human) for subcutaneous injection for the treatment of adults with the following blood cancers: previously untreated and relapsed or refractory follicular lymphoma, previously untreated diffuse large B-cell lymphoma (DLBCL), and previously untreated and previously treated chronic lymphocytic leukemia (CLL). The Genentech press release including Important Safety Information...

FDA grants regular approval to dabrafenib and trametinib combination for metastatic NSCLC with BRAF V600E mutation

Posted June 23, 2017

On June 22, 2017, the U.S. Food and Drug Administration granted regular approvals to dabrafenib and trametinib (TAFINLAR® and MEKINIST®, Novartis Pharmaceuticals Inc.) administered in combination for patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by an FDA-approved test. These are the first FDA approvals specifically for treatment of...

Reflecting With Gratitude on Gifts From My Patients

Posted June 22, 2017

A massive, 2-pound box of assorted chocolates sat opened on the table in the physicians’ workroom, with various pieces missing. There was no key on the underside of the box lid to help identify the chocolate types, so choosing a piece was a bit of a gamble. The candy was a gift from a patient...

Luis Raez, MD, on Mutation Testing in NSCLC

Posted June 16, 2017

Transcript: Luis Raez, MD: Nowadays, it’s very interesting. We have changed the standard of care for molecular testing. There was no molecular testing 4 or 5 years ago. Now, every new patient with lung cancer, especially nonsquamous non–small cell lung cancer, needs next-generation sequencing testing, generally from the tissue. And there is a lot of...

Dr. Elizabeth Kent Joins Florida Cancer Specialists & Research Institute

Posted June 16, 2017

Brought to you by a 100% FLASCO Membership Partner Nation’s Largest Independent Oncology Group  Welcomes New Physician in Jacksonville / Fleming Island Fleming Island, FL – June 15, 2017. . . Florida Cancer Specialists & Research Institute (FCS), the leading community oncology/hematology practice in the state, is pleased to announce that Elizabeth C. Kent, MD...

Participate in the ASCO Practice Census

Posted June 12, 2017

At ASCO, we believe in serving your practice/institution as well as you serve your patients with cancer. As you regularly need to monitor the health of your patients, ASCO regularly needs to gather information on what is happening in the oncology practice environment. I am writing to you today to encourage your practice or institution...

alexion

Alexion’s aHUS eCompendium

Posted June 12, 2017

aHUS eCompendium – A website designed to educate physicians and facilitate a timely and accurate diagnosis of atypical hemolytic syndrome (aHUS).  It provides important disease and diagnosis materials in the form of slide modules that you can download and customize for your own use.  There are several disease-related categories of slides including Complement, Complement Amplifying...

Florida Cancer Specialists’ Maria Ramos-Person Named 2017 Leukemia & Lymphoma Society’s Woman of the Year

Posted June 12, 2017

Brought to you by a 100% FLASCO Membership Partner Nation’s Largest Independent Medical Oncology/Hematology Practice Lends Support to Knock Out Blood Cancer Tampa, FL – June 8, 2017… Florida Cancer Specialists & Research Institute (FCS) is pleased to announce that Physician Liaison Manager Maria Ramos-Person was named the 2017 Woman of the Year by the Suncoast...

FDA Approves Drug to Visualize Malignant Tissue During Surgery – Drug Information Update

Posted June 8, 2017

FDA has approved Gleolan (aminolevulinic acid hydrochloride, ALA HCl), an optical imaging agent indicated in patients with gliomas (suspected World Health Organization grades III or IV on preoperative imaging) as an adjunct for visualization of malignant tissue during glioma surgery. Gleolan is the first fluorescing agent approved for use with gliomas.   Three prospective studies...

Florida Uniform Prior Authorization Form

Posted June 7, 2017

The Florida standardized PA goes into effect 7/11 and payers have 6 months to transition. Florida Rule for Uniform PA Form Florida Uniform PA Form Instructions Florida Uniform PA Form

Immunotherapy for Lung Cancer

Posted June 6, 2017

In the June 2017 issue of the Journal for the American Academy of Physician Assistants, there is an article: “Immunotherapy for Lung Cancer: Targeting the PD-1 Pathway” written by Sam Vafadar, PA-C, Department of Thoracic Medical Oncology, Moffitt Cancer Center. To read full article follow this link http://journals.lww.com/jaapa/Fulltext/2017/06000/Article.12.aspx.

Encouraging Phase II survival data for oral nintedanib in malignant pleural mesothelioma presented at ASCO 2017

Posted June 6, 2017

Ridgefield, Conn., June 5, 2017 – Boehringer Ingelheim today announced that Phase II results from LUME-Meso, a randomized, double-blind, placebo-controlled trial, have been presented as part of an Oral Abstract Session at the 2017 Annual Meeting of the American Society of Clinical Oncology (ASCO). Nintedanib, an oral triple angiokinase inhibitor, demonstrated improved progression-free survival (PFS,...

Conquer Cancer Foundation of ASCO Awards $5.65 Million to Support Cancer Research

Posted May 31, 2017

ALEXANDRIA, Va. – The Conquer Cancer Foundation of the American Society of Clinical Oncology (ASCO) has announced this year’s recipients of its Advanced Clinical Research Award in Breast Cancer, Career Development Awards, Young Investigator Awards, and Gianni Bonadonna Breast Cancer Research Fellowship. These awards recognize and support promising researchers in the field of oncology, with...

9th Annual Great Great Strides Together Highlights

Posted May 30, 2017

Great Strides Together Rapid Integrations Gallery Click the speaker’s name below to access their PowerPoint presentation. Welcome – Wael K. Barsoum, MD, President Cleveland Clinic Florida Immuno-Oncology – Vamsidhar Velcheti, MD and Jeanelle King, PA-C Opioid Prescribing – Dennis Patin, MD and Janet Villalobos, ARNP MDS – Rami Komrokji, MD and Sara Tinsley, PhD, ARNP,...

PAs Vote to Advance Profession to Meet Modern Healthcare Needs

Posted May 30, 2017

2017 Marks 50th Anniversary of PA Profession Contact: Carrie Munk, 571-319-4477, cmunk@aapa.org LAS VEGAS (May 18, 2017) — At the annual conference of the American Academy of PAs (AAPA), members of its House of Delegates approved Optimal Team Practice, a new policy intended to enhance the ability of PAs to meet the needs of patients and ensure...

FDA Broadens ceritinib Indication to Previously Untreated ALK-Positive Metastatic NSCLC

Posted May 30, 2017

On May 26, 2017, the U.S. Food and Drug Administration granted regular approval to ceritinib (ZYKADIA, Novartis Pharmaceuticals Corp.) for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. In April 2014, ceritinib received accelerated approval for patients with ALK-positive metastatic NSCLC whose...

FDA Approves First Cancer Treatment For Any Solid Tumor With A Specific Genetic Feature – microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR)

Posted May 25, 2017

On May 23, 2017, the U.S. Food and Drug Administration granted accelerated approval to pembrolizumab (KEYTRUDA, Merck & Co.) for adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options or with MSI-H...

Pebrolizumab (Keytruda): Advanced or Metastatic Urothelial Carcinoma

Posted May 18, 2017

Click here to read the corporate announcement.   On May 18, 2017, the U.S. Food and Drug Administration granted regular approval to pembrolizumab (KEYTRUDA, Merck and Co., Inc.) for patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment...

Pembrolizumab (KEYTRUDA) for classical Hodgkin lymphoma

Posted May 18, 2017

On March 14, 2017, The U.S. Food and Drug Administration granted accelerated approval to pembrolizumab (KEYTRUDA), Merck and Co., Inc.) for the treatment of adult and pediatric patients with refractory classical Hodgkin lymphoma (cHL), or those who have relapsed after three or more prior lines of therapy. Approval was based on data from 210 adult...

FDA grants accelerated approval to Merck’s KEYTRUDA® in combination with pemetrexed and carboplatin for initial treatment of metastatic non-squamous NSCLC

Posted May 11, 2017

Read Merck’s announcement. Click here for corporate press release On May 10, 2017, the U.S. Food and Drug Administration granted accelerated approval to pembrolizumab (KEYTRUDA® , Merck and Co., Inc.) in combination with pemetrexed and carboplatin for the treatment of patients with previously untreated metastatic non-squamous non-small cell lung cancer (NSCLC).   Approval was based...

Upcoming MACRA Webinars from ASCO

Posted May 11, 2017

ASCO is offering a new series of MACRA/Quality Payment Program webinars beginning next Monday, May 15.  The first webinar is focused on scoring for the quality measures and will provide a deep dive into the details – what you need to know to successfully report now and in the future.  Future webinars will look at...

FDA Grants Accelerated Approval to EMD Serono’s (BAVENCIO) avelumab for Urothelial Carcinoma

Posted May 10, 2017

On May 9, 2017, the U.S. Food and Drug Administration granted accelerated approval to avelumab (BAVENCIO, EMD Serono, Inc.) for patients with locally advanced or metastatic urothelial carcinoma whose disease progressed during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy. Approval was based on data from an open-label, single...

Novartis Receives FDA Approval for Rydapt® in Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML) and Three Types of Systemic Mastocytosis (SM)

Posted May 4, 2017

On April 28, 2017, the U.S. Food and Drug Administration approved midostaurin (RYDAPT, Novartis Pharmaceuticals Corp.) for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) who are FLT3 mutation-positive (FLT3+), as detected by an FDA-approved test, in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation. The FDA also approved...

Takeda Announces FDA Accelerated Approval of ALUNBRIGTM (brigatinib)

Posted May 4, 2017

On April 28, 2017, the U.S. Food and Drug Administration granted accelerated approval to brigatinib (ALUNBRIG tablets, Takeda Pharmaceutical Company Limited, through its wholly owned subsidiary ARIAD Pharmaceuticals, Inc.) for the treatment of patients with metastatic anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib. Approval...

astrazeneca

AstraZeneca Immunotherapy Wins First Approval In Bladder Cancer

Posted May 4, 2017

Learn More at https://www.imfinzi.com/    On May 1, 2017, the U.S. Food and Drug Administration granted accelerated approval to durvalumab (IMFINZI, AstraZeneca UK Limited) for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy or who have disease progression within 12 months of neoadjuvant or...

Florida Cancer Specialists’ Physicians & Executives Provide Leadership for National Community Oncology Conference

Posted May 2, 2017

Brought to you by a 100% FLASCO member partner Physicians, Administrators, Nurses, Pharmacists and Patient Advocates Share Latest Innovations in Cancer Care Washington, D.C. – May 1, 2017……… The 2017 Community Oncology Conference, which was convened April 27 – 28, 2017 in Washington, D.C., drew over 1300 oncologists, administrators, nurses, pharmacists, industry leaders and patient...

bayer health

FDA Approves Regorafenib for Liver Cancer

Posted April 27, 2017

On April 27, 2017 the U.S. Food and Drug Administration expanded the indications of regorafenib (STIVARGA, Bayer HealthCare Pharmaceuticals Inc.) to include the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib. Approval was based on an international, multicenter, randomized, double-blind, placebo-controlled trial of 573 patients with Child-Pugh A and...

FDA Approves Cancer Immunotherapy TECENTRIQ as Initial Treatment for Certain People with Advanced Bladder Cancer

Posted April 18, 2017

The FDA approved Tecentriq (atezolizumab) as a first-line treatment for people with locally advanced or metastatic urothelial carcinoma (mUC) who are not eligible for cisplatin chemotherapy. The Genentech press release including Important Safety Information is linked here. This approval is important news for a number of reasons: According to the American Cancer Society, it is...

FDA removes Risk Evaluation Management Strategies (REMS) for ESAs

Posted April 13, 2017

U.S. Food and Drug Administration removed the Risk Evaluation and Mitigation Strategy (REMS) requirements for the use of Epogen/Procrit and Aranesp to treat patients with anemia due to associated myelosuppressive chemotherapy. Below is the Agency’s announcement regarding this action: Epoetin alfa and darbepoetin alfa are Erythropoiesis-Stimulating Agents (ESAs), approved for the treatment of anemia (low...

FLASCO Spring Meeting Highlights

Posted April 6, 2017

Business of Oncology Spring Session Administrator Track Gallery On March 31st FLASCO Hosted the 2017 Business of Oncology. This year’s theme was Disruption as the Driver for Innovation and Change. Attendees gained cutting-edge perspectives on how DISRUPTIONS in healthcare policy will affect their oncology practice and the care of patients. The speakers and moderators examined...

Evaluate First Coast Service Options’ Services in 10 Minutes

Posted April 6, 2017

FCSO is requesting to hear from you!  Every year the Centers for Medicare & Medicaid Services (CMS) conducts the MAC Satisfaction Indicator survey to measure provider satisfaction with their MACs regarding the services FCSO perform for you. This survey is the best way for Medicare providers to share opinions directly with CMS about their experience...

Florida Cancer Specialists Foundation Names Lynn Rasys as Executive Director

Posted April 5, 2017

Brought to you by a 100% FLASCO Partner: Sarasota, FL – Apri 4, 2017. . . The Florida Cancer Specialist Foundation (FCSF), a non-profit 501c3 organization that provides financial assistance for non-medical living expenses to qualified cancer patients, announced the promotion of Lynn Rasys to Executive Director, following the retirement of Valerie Vance.  Previously, Lynn was...

astrazeneca

FDA Grants Full Approval for TAGRISSO

Posted April 4, 2017

FLASCO Diamond Corporate Member, AstraZeneca, is pleased to inform you that the US Food and Drug Administration (FDA) granted full approval for TAGRISSO® (osimertinib) 80mg once-daily tablets, for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an FDA-approved test, whose disease has progressed...

FDA approves first treatment for rare form of skin cancer

Posted March 26, 2017

The U.S. Food and Drug Administration today granted accelerated approval to Bavencio (avelumab) for the treatment of adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma (MCC), including those who have not received prior chemotherapy. This is the first FDA-approved treatment for metastatic MCC, a rare, aggressive form of skin cancer....

Congratulations to Dr. Sonia Orcutt

Congratulations to Dr. Sonia Orcutt

Posted March 26, 2017

Congratulations to Dr. Sonia Orcutt for being a recipient of a FLASCO Travel Award!  Dr. Orcutt used her grant to attend this year’s Society of Surgical Oncology Annual Cancer Symposium.  Below is what Dr. Orcutt shared about her attendance. “The primary conference for my specialty is the Society of Surgical Oncology Annual Cancer Symposium. Each...

FDA Approves EMD Serono’s Avelumab for Merkel Cell Carcinoma

Posted March 24, 2017

The U.S. Food and Drug Administration today granted accelerated approval to Bavencio (avelumab) for the treatment of adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma (MCC), including those who have not received prior chemotherapy. This is the first FDA-approved treatment for metastatic MCC, a rare, aggressive form of skin cancer....

New NCCN Radiation Therapy Compendium™ Aids in Decision-Making for Patients with Cancer

Posted March 23, 2017

Launched during the NCCN 22nd Annual Conference, the new NCCN Radiation Therapy Compendium™ provides a single access point for radiation therapy recommendations within the NCCN Guidelines®. [FORT WASHINGTON, PA – March 23, 2017] Radiation therapy (RT), either alone or in combination with chemotherapy or surgery, is one of the most common treatment options for people...

FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Adult and Pediatric Patients with Classical Hodgkin Lymphoma (cHL) Refractory to Treatment, or Who Have Relapsed After Three or More Prior Lines of Therapy

Posted March 16, 2017

On March 14, 2017, The U.S. Food and Drug Administration granted accelerated approval to pembrolizumab (KEYTRUDA), Merck and Co., Inc.) for the treatment of adult and pediatric patients with refractory classical Hodgkin lymphoma (cHL), or those who have relapsed after three or more prior lines of therapy. Approval was based on data from 210 adult...

FDA approves ribociclib in combination with an aromatase inhibitor for HR-positive, HER2-negative advanced or metastatic breast cancer

Posted March 16, 2017

On March 13, 2017, the U.S. Food and Drug Administration approved ribociclib (KISQALI®, Novartis Pharmaceuticals Corp.), a cyclin-dependent kinase 4/6 inhibitor, in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. Approval was...

Florida Cancer Specialists & Research Institute Expands In-House Pathology Laboratory Team

Posted March 8, 2017

Brought to you by FLASCO 100% Membership Partner: Fort Myers, FL – March 8, 2017. . .Florida Cancer Specialists & Research Institute (FCS), the leading community oncology/hematology practice in the state, has one of the most advanced pathology laboratories in the state focusing on the diagnosis and treatment of cancer.  Located in Fort Myers, FL,...

Florida Cancer Specialists & Research Institute Welcomes New Physicians and New Location in Martin County

Posted March 6, 2017

Brought to you by 100% Membership Partner: Dr. Guillermo Abesada-Terk and Dr. Alpana Desai Join Nation’s Largest Independent Oncology Group  Stuart, FL – March 6, 2017. . . Florida Cancer Specialists & Research Institute (FCS), the leading community oncology/hematology practice in the state, is pleased to announce that Alpana Desai, MD and Guillermo Abesada-Terk, MD...

Dr. Ferdy Santiago Joins Florida Cancer Specialists & Research Institute

Posted March 3, 2017

Brought to you by 100% Membership Partner: Dr. Ferdy Santiago Joins Florida Cancer Specialists & Research Institute Nation’s Largest Independent Oncology Group Welcomes New Physician in Collier County Naples, FL – March 2, 2017…Florida Cancer Specialists & Research Institute (FCS), the leading community oncology/hematology practice in the state, is pleased to announce that Ferdy Santiago, MD has...

FDA Approves Lexicon Drug XERMELO™ (telotristat ethyl) 250 mg As First And Only Oral Treatment For Carcinoid Syndrome Diarrhea In Cancer Patients With Metastatic Neuroendocrine Tumors

Posted March 1, 2017

The U.S. Food and Drug Administration approved Xermelo (telotristat ethyl) tablets in combination with somatostatin analog (SSA) therapy for the treatment of adults with carcinoid syndrome diarrhea that SSA therapy alone has inadequately controlled. Carcinoid syndrome is a cluster of symptoms sometimes seen in people with carcinoid tumors. These tumors are rare, and often slow-growing....

incyte

National Treatment Guidelines for Myeloproliferative Neoplasms

Posted February 24, 2017

lncyte Corporation is pleased to announce that ruxolitinib (Jakafi®) has been included as a recommended treatment for myelofibrosis in the new NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Myeloproliferative Neoplasms (MPNs). Myelofibrosis is a rare bone marrow cancer. Ruxolitinib (Jakafi®) is the first and only therapy that is FDA approved for patients with...

FDA Expands Indication for REVLIMID® (lenalidomide) as a Maintenance Treatment for Patients with Multiple Myeloma Following Autologous Hematopoietic Stem Cell Transplant (auto-HSCT)

Posted February 23, 2017

On February 22, 2017, the U.S. Food and Drug Administration approved lenalidomide (Revlimid®, Celgene Corp.) as maintenance therapy for patients with multiple myeloma following autologous stem cell transplant. In 2006, lenalidomide, an orally administered thalidomide analogue, received FDA approval for use with dexamethasone in patients with multiple myeloma who received at least one prior therapy....

Support SB 528/ SB 530 by Senator Steube – FAIL FIRST/STEP THERAPY

Posted February 20, 2017

While health insurance utilization management (restrictions on access) procedures such as fail first/step therapy may be appropriate measures to control costs, they have also been over-utilized under the cloak of confusion surrounding health care and to the detriment of numerous patients across Florida. Contact your legislator today to let them know, ultimately, healthcare professionals, not...

Funding for Mary Brogan Breast and Cervical Cancer Early Detection Program

Posted February 20, 2017

The Mary Brogan Breast and Cervical Cancer Early Detection Program provides lifesaving cancer screenings for medically underserved women between the ages of 50 and 64 who have incomes below 200% of the federal poverty level. For 2017, ACS CAN asks that the state fund the program at a level equal to one-half of the U.S....

Prosigna Coverage with BCBS FL

Posted February 15, 2017

This morning BCBS FL published an updated policy for Assays of Genetic Expression in Tumor Tissue as a Technique to Determine Prognosis in Patients with Breast Cancer.  Prosigna now has the same coverage criteria as Oncotype Dx.  Below is the coverage criteria.  The full policy can be found at www.bcbsfl.com, go under the provider tab,...

FLASCO Hosts “Living with Metastatic Breast Cancer” Educational Luncheon

Posted February 15, 2017

TALLAHASSEE, Fla. — The Florida Society of Clinical Oncology (FLASCO) hosted a free “Living with Metastatic Breast Cancer” luncheon this afternoon about treatment and support for people who have this advanced type of cancer and their caregivers. Metastatic breast cancer, also known as stage IV breast cancer, is when the cancer cells have travelled to...

Oplinc Best Practices Review

Posted February 10, 2017

Oplinc is a national organization that was founded with the purpose of developing a collaborative environment within the oncology community. Oplinc is dedicated to preserving patients’ access to cancer services through the facilitation of education, communication and networking between physicians, pharmaceutical manufacturers and payers involved in the delivery of quality cancer care. Use the link...

NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) and NCCN Drugs & Biologics Compendium (NCCN Compendium®) for Head and Neck Cancers. These NCCN Guidelines® are currently available as Version 1.2017.

Posted February 8, 2017

  NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) and NCCN Drugs & Biologics Compendium (NCCN Compendium®) for Head and Neck Cancers. These NCCN Guidelines® are currently available as Version 1.2017.  ·         Cancer of the Oral Cavity o    For clinical stage T1-2, N0, re-resection has been made the preferred...

Humana Issues Positive Coverage Decision for NanoString’s Prosigna® Breast Cancer Assay

Posted February 6, 2017

SEATTLE, Jan. 31, 2017 (GLOBE NEWSWIRE) — NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that Humana has issued a positive coverage decision for the Prosigna® Breast Cancer Gene Signature Assay. Humana and its more than 13 million members join other payors now covering...

Bristol-Myers Squibb Receives FDA Approval for Opdivo (nivolumab) in Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma, a Type of Bladder Cancer

Posted February 6, 2017

PRINCETON, N.J.–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE:BMY) today announced the U.S. Food and Drug Administration (FDA) has approved Opdivoinjection, for intravenous use for the treatment of patients with locally advanced or metastatic urothelial carcinoma (mUC) who have disease progression during or following platinum-containing chemotherapy or have disease progression within 12 months of neoadjuvant or adjuvant treatment...

World Cancer Day: A Time for Action

Posted February 6, 2017

Brought to you by 100% FLASCO Membership Partner By Dr. William N. Harwin – Founder and President, Florida Cancer Specialists & Research Institute Fort Myers, FL – February 3, 2017…As an oncologist for over 30 years, I feel privileged to be able to care for cancer patients. I think about cancer every day and I...

flasco logo

Battle of the Brothers (Bryan Brothers) and Usta Men’s Pro Tennis Tournament at Kiwi Tennis Club-Indian Harbor Beach, Florida

Posted January 27, 2017

Discounts for FLASCO members! Oncology Resource Networks and Craig Deligdish, MD, are honored to serve as the Title Sponsor for the Bryan Brothers Exhibition and the First Annual KIWI USTA Men’s Pro Tennis Tournament. The Bryan Brothers event will be held on Saturday, February 18th and the First Annual Men’s USTA Pro Tennis Tournament will...

Physicians Education Resource® Partners with the Florida Society of Clinical Oncology

Posted January 26, 2017

PER® and FLASCO to collaborate to develop cancer awareness and provide professional educational opportunities that enhance their missions (Cranbury NJ, January XX)- Physicians Education Resource®, LLC (PER®), has partnered with the Florida Society of Clinical Oncology, (FLASCO), to continue to promote education to the oncology health care community, announced PER® President Phil Talamo In making...

EXTENDED DEADLINE: MD/PhD Researchers now eligible to apply for the RTAF Award

Posted January 25, 2017

Apply by February 1 to be considered. MD/PhD researchers are encouraged to submit an application by Wednesday, February 1, for the ASH Research Training Award for Fellows. This award helps fellows in training pursue careers in academic hematology by ensuring they have protected time for conducting research and gaining expertise to position them to be...

Dr. Mitchell B. Weisberg Joins Florida Cancer Specialists & Research Institute

Posted January 18, 2017

Brought to you by FLASCO 100% Membership Partner: Palm Coast, FL – January 16, 2017…Florida Cancer Specialists & Research Institute (FCS), the leading community oncology/hematology practice in the state, is pleased to announce that Mitchell B. Weisberg, MD has joined the practice and is seeing patients at the Palm Coast office of Florida Cancer Specialists, located...

FLASCO Administrator Network Patient Support Resources Webinar

Posted January 12, 2017

  On January 12, 2017, the FLASCO Administrator Network hosted its first webinar. The topic was Patient Support Resources, and it featured experts from community oncology  and hospital settings, who shared their tips, helpful hints, and tools of the trade regarding assistance programs and resources available for cancer patients. Congratulations to Maggie Wiegandt, MBA and Gail...

NCCN has published updates to theNCCN Guidelines® and NCCN Compendium® for Penile Cancer.

Posted January 12, 2017

NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) and the NCCN Drugs & Biologics Compendium (NCCN Compendium®) for Penile Cancer. These NCCN Guidelines® are currently available as Version 1.2017. Primary treatment Tis or Ta disease (PN-1) The second option was revised: “Wide local excision .” The fifth option was...

FLASCO Volunteer Application

Posted January 10, 2017

The FLASCO Volunteer Application is currently open for 2017 FLASCO Committee, Board of Directors, and Liaison opportunities through January 27th! FLASCO volunteers are the heart of our Society and through volunteer service you have the opportunity to take your membership to the next level. FLASCO volunteers provide leadership and insight to the Society’s activities and...

Consolidation Ripples Out From Florida

Posted January 3, 2017

Florida is a leader in the consolidation trend, topping the nation in the number of practices that have closed, merged, or been acquired in recent years, according to the Community Oncology Alliance (COA). Most practices have affiliated with hospitals or joined large groups like Florida Cancer Specialists, one of the nation’s biggest physician-owned oncology networks....

foundation medicine

Foundation Medicine Receives FDA Approval of FoundationFocus™ CDxBRCA as a Companion Diagnostic for Rubraca™ (rucaparib) for the Treatment of Women with Ovarian Cancer

Posted December 29, 2016

–FDA approval of FoundationFocus CDxBRCA marks important progress towards Foundation Medicine’s development of a comprehensive universal companion diagnostic assay across multiple tumor types to advance precision medicine in oncology–   Foundation Medicine, Inc.  announced that the U.S. Food and Drug Administration (FDA) has approved FoundationFocus™ CDxBRCA for use as a companion diagnostic to aid in identifying women with ovarian cancer...

Expert Emphasizes Importance of Liquid Biopsies in Lung Cancer

Posted December 28, 2016

Plasma- and urine-based assays designed to detect actionable mutations in patients with non–small cell lung cancer (NSCLC) are changing the face of treatment for these patients, according to Luis E. Raez, MD. The liquid biopsies, he says, provide a more convenient and quicker alternative to the standard tissue biopsy. And, if a target is detected,...

Expert Highlights Ongoing Progress in ALK+ NSCLC

Posted December 28, 2016

Frontline therapy for patients with ALK-positive non–small cell lung cancer (NSCLC) is poised to change in the coming years, as researchers continue to explore agents beyond crizotinib (Xalkori). “[The ALK-positive population] is sort of a small percentage of the patients with adenocarcinoma of the lung,” said Lowell L. Hart, MD, during an interview at the...

The Role of Biomarker Testing in Advanced NSCLC

Posted December 22, 2016

In partnership with Boehringer Ingelheim, FLASCO is pleased to provide the following video on the importance of biomarker testing in NSCLC.  Presented by Mohammad Jahanzeb, MD, FACP, Professor of Clinical Medicine & Hematology Oncology at University of Miami’s Miller School of Medicine, the video touches on the importance of biomarker testing, continuing the focus on...

Edgardo Santos Speaks On Exciting Advancements in Field Of Lung Cancer

Posted December 22, 2016

FLASCO member, Edgardo S. Santos, MD, medical oncology, internal medicine, Boca Raton Regional Hospital, discusses exciting advancements in the field of lung cancer. Santos shared this insight during the 2016 OncLive State of the Science Summit on Lung Cancer.

President Obama Signs 21st Century Cures Legislation

Posted December 15, 2016

President Obama Signs 21st Century Cures Legislation In addition to the original intent of the legislation to speed the discovery, development, and delivery of cures, the bill became a vehicle for many other health care priorities including funding to address the opioid crisis, reforms to the mental health system and changes to hospital payments.President Barack...

taiho oncology

Taiho Oncology Patient Assistant Program

Posted December 12, 2016

Taiho Oncology Patient Assistant Program (Taiho Oncology PAP) will become effective Jan 1, 2017. A Medicare Part D patient applying for the Taiho Oncology Patient Assistance Program (PAP) in 2017 who falls below 150% of the Federal Poverty Level, will first need to apply for the Medicare Part D Low-Income Subsidy (LIS) program. Patients currently...

biodesix

New Peer-Reviewed Published Data is Now Available on VeriStrat

Posted December 10, 2016

The study on VeriStrat was published in the British Journal of Cancer and validates the prognostic value and utility of VeriStrat in patients diagnosed with non-small cell lung cancer (NSCLC) in the front line setting. Follow this link to view publication. Brought to you by Biodesix

Florida Cancer Specialists & Research Institute Announces New Office Location in Ocala, FL

Posted December 8, 2016

Brought to you by a FLASCO 100% Membership Partner: Nation’s Largest Independent Oncology/Hematology Practice Adds Clinic in Marion County Ocala, FL – December 7, 2016…Florida Cancer Specialists & Research Institute (FCS), the leading community oncology/hematology practice in the state, announced today that a new clinical location has opened in Ocala, FL. The address of the...

Assignment of Product-Specific HCPCS Code for Portrazza® (necitumumab) for Injection

Posted December 8, 2016

We are sending this communication on behalf of Eli Lilly and Company to announce the assignment of a product‐specific Healthcare Common Procedure Coding System (HCPCS) code for Portrazza® (necitumumab) for injection. The new code, J9295, is defined as “injection, necitumumab, 1 mg.” This code is effective January 1, 2017.1    Trade Name HCPCS Code Strength...

FDA Approves Avastin for Specific Type of Ovarian Cancer

Posted December 8, 2016

The FDA granted approval to Avastin in combination with chemotherapy for the treatment of platinum-sensitive recurrent ovarian cancer (psOC), representing the first new treatment option for women with psOC in the U.S. in more than a decade [press release]. Ovarian cancer causes more deaths than any other gynecological cancer in the U.S., and in 2016,...

The Centers for Medicare & Medicaid Services (CMS) has assigned a permanent Healthcare Common Procedure Coding System (HCPCS) code specific to IMLYGIC®

Posted December 8, 2016

INDICATION IMLYGIC is a genetically modified oncolytic viral therapy indicated for the local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma recurrent after initial surgery. IMLYGIC has not been shown to improve overall survival or have an effect on visceral metastases The new code, J9325, is defined as “injection, talimogene laherparepvec,...

ccms logo

Scholarship Applications for Medical & Healthcare Students are Due March 31st

Posted December 8, 2016

Awards from the Foundation of Collier County Medical Society support our future healthcare professionals Collier County, FL (December 6, 2016)—The board of directors of the Foundation of Collier County Medical Society (CCMS) is accepting applications through March 2017 for its two scholarship awards: the Dr. William Lascheid Memorial Scholarship for medical students and Healthcare Student...

FDA Approves Bevacizumab for Platinum-Sensitive Ovarian Cancer

Posted December 7, 2016

FDA Approves Genentech’s Avastin® (Bevacizumab) Plus Chemotherapy for a Specific Type of Advanced Ovarian Cancer Approval based on two large Phase III studies including GOG-0213 that showed a five month overall survival difference for women with platinum-sensitive recurrent ovarian cancer on Avastin plus chemotherapy compared to chemotherapy alone In the United States, Avastin is now...

Dr. Bennett Yu Joins Florida Cancer Specialists & Research Institute

Posted December 6, 2016

Brought to you by a FLASCO 100% Membership Partner: Naples, FL – December 5, 2016…Florida Cancer Specialists & Research Institute (FCS), the leading community oncology/hematology practice in the state, is pleased to announce that Bennett Yu, MD has joined the practice and is seeing patients at two FCS locations. Dr. Yu will practice at the...

US Oncology logo

Blood & Cancer Center Joins Florida Cancer Affiliates

Posted December 2, 2016

Ocala, Fla. (December 1, 2016) — Florida Cancer Affiliates (FCA), a premier provider of advanced cancer care services in Florida, announced that Blood & Cancer Center has joined its practice. Anju Vasudevan, M.D., and Cecil Robertson, M.D., oncologists and hematologists with Blood & Cancer Center, will unite with Florida Cancer Affiliate’s group of physicians to...

House Passes Medical Cures Bill – 21st Century Cures Act

Posted December 1, 2016

The House on Wednesday passed a medical innovation bill aimed at curing diseases, with the measure securing bipartisan support after months of negotiations. The legislation, known as the 21st Century Cures Act, passed 392-26. It seeks to speed up the Food and Drug Administration’s approval of new drugs while investing new money in medical research. The package...

teva oncology

BEN-40399 BENDEKA Associations J Code Alert

Posted November 30, 2016

On November 1st 2016, the Center for Medicare and Medicaid Services (CMS) published the 2017 HCPCS Code set, which included a permanent, UNIQUE J code for BENDEKA® (bendamustine HCI) Injection. Effective January 1, 2017, the Permanent J code for BENDEKA® will be J 9034 Injection, bendamustine HCI (bendeka), 1 mg. The published information by CMS...

Posted November 30, 2016

On November 1st 2016, the Center for Medicare and Medicaid Services (CMS) published the 2017 HCPCS Code set, which included a permanent, UNIQUE J code for BENDEKA® (bendamustine HCI) Injection. Effective January 1, 2017, the Permanent J code for BENDEKA® will be J 9034 Injection, bendamustine HCI (bendeka), 1 mg. The published information by CMS...

asco-elections

Vote in ASCO Election

Posted November 17, 2016

Through its annual elections, ASCO invites its members to choose their future leaders and guide the direction of their Society. Twelve distinguished ASCO members have been selected by the ASCO Nominating Committee as candidates for open leadership positions.

MedPAC Holds Meeting on Provider Consolidation

Posted November 17, 2016

MedPAC Holds Meeting on Provider Consolidation On November 3, the Medicare Payment Advisory Committee (MedPAC) hosted a meeting on provider consolidation and its effect on the Medicare system. The discussion primarily focused on the trends towards horizontal and vertical integration among providers – essentially hospitals buying physician practices and then billing the services through their...

NCCN Challenges Medical Community to “Just Bag It” to Eradicate Deadly Medical Error

Posted November 16, 2016

NCCN is excited to share its new patient safety campaign, which was announced at a press conference last week in Philadelphia. As part of its mission to improve the quality, effectiveness, and efficiency of cancer care so that patients can live better lives, the National Comprehensive Cancer Network® (NCCN®) has announced the launch of Just Bag It: The...

Genentech Launches imCORE™, A Global Network of Cancer Immunotherapy Centers of Excellence

Posted November 15, 2016

Genentech, a member of the Roche Group, has launched the global cancer immunotherapy Centers of Research Excellence (imCORE) Network. This network brings together many of the world’s leading scientific and clinical experts in cancer immunotherapy to collaborate in investigating the most promising new treatment approaches. The goal is to rapidly initiate pre-clinical and clinical research...

Florida Blue and Florida Cancer Specialists Introduce Accountable Cancer Provider Program

Posted November 15, 2016

Brought to you by a FLASCO 100% Membership Partner: Fort Myers, FL – November 14, 2016…Florida Blue, Florida’s Blue Cross and Blue Shield company, and Florida Cancer Specialists & Research Institute (FCS), the leading community oncology/hematology practice in the state, are proud to announce a new agreement implementing an accountable provider program specific to the treatment...

FDA approves nivolumab for recurrent or metastatic squamous cell carcinoma of the head and neck

Posted November 10, 2016

On November 10, 2016, the U. S. Food and Drug Administration approved nivolumab (OPDIVO Injection, Bristol-Myers Squibb Company), for the treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) with disease progression on or after a platinum-based therapy. Approval was based on data from an international, multi-center, open-label,...

COA

CVS Indicates Reversal of Decision to Block Oncology Clinics Dispensing Patients’ Drugs

Posted October 31, 2016

The Community Oncology Alliance (COA) has recently learned that CVS Health is indicating it will not proceed with restricting cancer patients from receiving their medications from oncology practices that dispense medications. Previously, CVS had notified patients that, beginning January 1, 2017, their oncologists’ pharmacies would be considered “out of network” and medications would only be...

Astellas to Acquire Ganymed Pharmaceuticals

Posted October 31, 2016

TOKYO and MAINZ, Germany, Oct. 28, 2016 /PRNewswire/ — Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) and Ganymed Pharmaceuticals AG (CEO; Özlem Türeci, “Ganymed”), a biopharmaceutical company located in Mainz, Germany which focuses on the development of antibodies against cancer, announced today that Astellas and Ganymed’s shareholders have entered into an...

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) and the NCCN Drugs & Biologics Compendium (NCCN Compendium®) for Non-Small Cell Lung Cancer

Posted October 27, 2016

NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) and the NCCN Drugs & Biologics Compendium (NCCN Compendium®) for Non-Small Cell Lung Cancer. These NCCN Guidelines® are currently available as Version 2.2017.  Metastatic Disease (NSCL-17) Testing results modified for PD-L1: PD-L1 positive and EGFR, ALK, ROS1 negative or unknown Subsequent...

FDA Approves Cancer Immunotherapy TECENTRIQ For People With Specific Type Of Metastatic Lung Cancer

Posted October 20, 2016

On October 18, 2016, FDA approved atezolizumab (TECENTRIQ, Genentech Oncology) for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose disease progressed during or following platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving atezolizumab. Atezolizumab is a programmed...

CMS Finalizes the New Medicare Quality Payment Program  – MACRA

Posted October 14, 2016

On October 14, HHS finalized its policy implementing the Merit-Based Incentive Payment System (MIPS) and the Advanced Alternative Payment Model (APM) incentive payment provisions in the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA), collectively referred to as the Quality Payment Program. Accompanying the announcement is a new Quality Payment Program website, which will explain the...

New Resource about ICD-10 Coding and Use of the JW Modifier

Posted October 13, 2016

CMS has communicated that the ICD-10 flexibilities expire on October 1, 2016. At this time, providers will be required to code to accurately reflect the clinical documentation in as much specificity as possible, as per the required coding guidelines. In addition, effective January 1, 2017, CMS will require the use of the JW modifier on...

Announcing a Unique C-code for a Genentech BioOncology(R) product

Posted October 5, 2016

The following is important information regarding a unique C-code that was recently assigned to TECENTRIQ™ (atezolizumab) by the Centers for Medicare & Medicaid Services (CMS). The C-code for TECENTRIQ is C9483 (Injection, atezolizumab, 10 mg). The unique C-code goes into effect on October 1, 2016. Payers may require its use until a permanent J-code is...

NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Acute Lymphoblastic Leukemia and Survivorship

Posted October 5, 2016

NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Acute Lymphoblastic Leukemia. These NCCN Guidelines® are currently available as Version 2.2016.  The Discussion section has been updated to reflect the changes in the algorithm. (MS-1) *For your reference, the previous update (Version 1.2016) to the NCCN Guidelines for Acute...

teva oncology

INTevaGENCE: The Expert Forum for Advanced Oncology Care

Posted September 30, 2016

FLASCO is pleased to make you aware of a new offering from Teva Oncology; INTevaGENCE: The Expert Forum for Advancing Oncology Care. INTevaGENCE offers an online expert forum where seasoned presenters bring information, tools, instruction, and expert perspectives. The topics covered in INTevaGENCE are Oncology Nurse Navigation, Continuous Improvement of Quality and Patient Satisfaction and...

AHCA P & T Committee Meeting Summary

Posted September 29, 2016

  The Agency for Health Care Administration conducted a Pharmaceutical & Therapeutics (P&T) Committee meeting this past Friday, September 23.  Most notable was the revision to remove oncology drugs and therapy from the fee schedule rule because changes can only be made to the fee schedules through an administrative rule process which is quite lengthy....

Free PQRS Reporting Now Available Through QOPI®; No Additional Reporting Required 

Posted September 29, 2016

ASCO is pleased to announce that oncology practices can now complete all of their Physician Quality Reporting System (PQRS) requirements through the Quality Oncology Practice Initiative (QOPI®) platform. All users will be able to use the QOPI system to fulfill the Oncology Measures Group set of seven measures for PQRS reporting. QOPI is free to...

NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Genetic/Familial High-Risk Assessment: Colorectal and Kidney Cancer

Posted September 29, 2016

NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Genetic/Familial High-Risk Assessment: Colorectal. These NCCN Guidelines® are currently available as Version 2.2016.  The Discussion section has been updated to reflect the changes in the algorithm. (MS-1) *For your reference, the previous update (Version 1.2016) to the NCCN Guidelines for...

NCCN has published updates to the NCCN Guidelines® and NCCN Compendium® for Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL).

Posted September 29, 2016

NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) and NCCN Drugs & Biologics Compendium (NCCN Compendium®) for Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL). These NCCN Guidelines® are currently available as Version 1.2017.  ·         The NCCN Guidelines for CLL/SLL (previously included as part of NCCN Guidelines for Non-Hodgkin’s Lymphomas) have...

NCCN has published updates to the NCCN Guidelines® for Genetic/Familial High-Risk Assessment: Breast and Ovarian.

Posted September 22, 2016

NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Genetic/Familial High-Risk Assessment: Breast and Ovarian. These NCCN Guidelines® are currently available as Version 1.2017. Breast and Ovarian Cancer Risk Assessment (BR/OV-1) First column, 2nd bullet, “An individual with a breast cancer diagnosis meeting any of the following” For the 4th...

ASCO, ASTRO and SSO update guideline on postmastectomy radiotherapy

Posted September 22, 2016

Three leading national cancer organizations today issued a joint clinical practice guideline update for physicians treating women with breast cancer who have undergone a mastectomy. The update provides additional considerations for physicians to determine which patients might benefit from postmastectomy radiotherapy (PMRT). “We still don’t have a single, validated formula that can determine who needs...

Congratulations to Sylvester Comprehensive Cancer Center

Posted September 16, 2016

We are pleased to announce that the Sylvester Comprehensive Cancer Center, part of UHealth – the University of Miami Health System, has earned a Lung Cancer Screening Center Designation by  the American College of Radiation.   The lung cancer screening program at Sylvester Comprehensive Cancer Center, part of UHealth – the University of Miami Health...

AfBA logo

AfPA and Cancer Care Explore the Cancer Treatment Experience

Posted September 16, 2016

  Cancer patients may feel under-informed about their diagnosis, overwhelmed by out-of-pocket expenses and unable to carry out day-to-day activities – despite being confident about their quality of care. This narrative emerged during an August 9 webinar co-hosted by the Alliance for Patient Access and Cancer Care, which explored Cancer Care’s 2016 Patient Access & Engagement Report. The report included...

Cigna – JW Modifier Start Date Update

Posted September 16, 2016

FLASCO recently contacted Cigna on behalf of our 2,000 plus members requesting that Cigna reconsider the start date for the JW Modifier. It was pointed out to Cigna that Medicare had pushed the implementation back to 1/1/17. This will allow practices to ensure appropriate IT resources are in place to report the waste appropriately. At...

Comprehensive Cancer Center at Broward Health Medical Center Named Affiliate Member of University of Florida for NRG Oncology

Posted September 16, 2016

The Comprehensive Cancer Center at Broward Health Medical Center (BHMC) has been granted Affiliate Membership by NRG Oncology – a non-profit research organization that conducts oncologic clinical research and broadly disseminates study results for informing clinical decision-making and healthcare policy. Broward Health North was also approved as an affiliate site. The membership grants BHMC the...

Suncoast Cancer Institute Goes Above and Beyond

Posted September 16, 2016

Suncoast Cancer Institute in Sarasota, FL founder, Dr. Penny Heinrich, and Amy Akins, BSN, RN, OCN, both diligently worked on a patient’s behalf in concert with Walgreen’s to facilitate a lower drug cost. A Tarceva patient originally filled a prescription and was told they would have a $2000 co-pay amount, that the patient was unable...

ASCO, SGO Update Guidelines On Role Of Chemo For Advanced Ovarian Cancer

Posted September 16, 2016

  All patients with stage IIIC or IV epithelial ovarian cancer associated with high clinical risk or a low likelihood of optimal surgical resection should receive neoadjuvant chemotherapy, according to a new clinical practice guideline. The recommendation pertains to women who have high-risk features such as older age or a high comorbidity burden or who...

Moffitt Cancer Center ranked #6 in U.S. News & World Report’s Best Hospitals

Posted September 16, 2016

  Congratulations to the Moffitt Cancer Center on being ranked Number. 6 on U.S. News & World Report’s Best Hospitals for Cancer rankings released Tuesday. This is up from No. 18 last year and makes Moffitt the top ranked cancer hospital in the Southeast and in the state of Florida.  Moffitt Cancer Center maintains 100%...

CVS Cuts Coverage of Dozens of Drugs in Exclusion Expansion

Posted September 16, 2016

CVS Health Corp. will add 35 products to its lists of excluded drugs in 2017 and no longer cover some treatments for cancer and diabetes, in an aggressive move to favor lower-priced treatments and target what the company called “hyperinflation” of some other products. The drug benefit manager will remove coverage for Novartis AG’s leukemia...

foundation medicine

Foundation Medicine Launches Blood-Based Liquid Biopsy, FoundationACT

Posted September 16, 2016

  Foundation Medicine has launched a new assay, FoundationACT (Assay for Circulating Tumor DNA), a rigorously validated and highly accurate blood-based circulating tumor DNA (ctDNA) assay that provides patients and oncologists with a new option for comprehensive genomic profiling when a tissue biopsy is not feasible or when tissue is not available. By analyzing cell-free...

Infusion Pump Billing Update

Posted September 16, 2016

CMS recently provided additional clarification to MACs and providers regarding reimbursement for prolonged drug and biological infusions that are started in the office or outpatient hospital and are associated with care that is billed incident to a physician service using an external pump. In order for Medicare to pay for a drug or biological, the...

Genentech’s TECENTRIQ Upcoming Webinars

Posted September 15, 2016

On behalf of Genentech, you are invited to attend one of three webcasts across two days that span lunch times across 3 time zones: Introducing TECENTRIQ: The First and Only FDA-Approved Anti-PDL1 Immunotherapy for Previously Treated Locally Advanced Metastatic Urothelial Carcinoma September 28, 2016 Fairooz Kabbinavar, MD – UCLA, Los Angeles, CA 3:00pm ET, 2:00pm...

ASCO Annual Meeting Collective Wisdom

Posted September 12, 2016

Novartis Oncology is pleased to invite you to virtually attend sessions from the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting. To access the virtual platform please register at www.asco2016.com/FLASCO to begin viewing the recorded video sessions in the single track of your choice and learn about the practice-changing advances in oncology presented at...

Online App Available: Mapping Florida’s Cancer Screening Providers

Posted September 9, 2016

I am happy to announce the online cancer screening provider map is finally available! This has been a long time coming and I hope that you will take time to share this with your partners and colleagues. With how long it took you might imagine it is perfect, but I do not doubt there are...

Sylvester Earns Lung Cancer Screening Center Designation by the American College of Radiology

Posted September 9, 2016

The lung cancer screening program at Sylvester Comprehensive Cancer Center, part of UHealth – the University of Miami Health System, has been designated an American College of Radiology (ACR) Lung Cancer Screening Center. The voluntary designation signifies that the program and protocol meet the requirements set forth by the ACR lung cancer screening committee. It...

US Oncology logo

Woodlands Medical Specialists Joins The US Oncology Network

Posted September 6, 2016

Union strengthens Woodlands’ ability to remain independent, providing access to vast resources Pensacola, Florida (September 6, 2016) – Woodlands Medical Specialists, a physician-owned multi-specialty outpatient clinic serving Florida’s Panhandle region, has joined The US Oncology Network. The Network provides strong and comprehensive practice management capabilities and value-based care expertise that are critical for large practices...

Dr. Ayman Barakat Joins Florida Cancer Specialists in Hernando County

Posted August 17, 2016

Spring Hill, FL – August 16, 2016. . . Florida Cancer Specialists & Research Institute (FCS), the leading community oncology/hematology practice in the state, is pleased to announce that Ayman Barakat, MD has joined the practice and is seeing patients at two FCS locations in Hernando County, FL. Dr. Barakat will practice at the Brooksville...

BUCCANEERS AND FLORIDA CANCER SPECIALISTS RENEW PARTNERSHIP

Posted August 12, 2016

Tampa, FL – August 10, 2016……… The Tampa Bay Buccaneers and Florida Cancer Specialists & Research Institute (FCS) announced that they have renewed their partnership with a multi-year deal. The work being performed by Florida Cancer Specialists & Research Institute (FCS)in the research and treatment of cancer is making a real difference in the lives...

NCCN Guidelines Updated

Posted August 11, 2016

NCCN has published NEW NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) with NCCN Evidence Blocks™ for the following disease type: Testicular Cancer, Version 2.2016 NCCN has published updates to the NCCN Guidelines® and NCCN Drugs & Biologics Compendium (NCCN Compendium®) for Small Cell Lung Cancer. These NCCN Guidelines are currently available as Version 1.2017.  Adjuvant...

NCCN has published updates to the NCCN Guidelines for Breast Cancer Screening and Diagnosis.

Posted August 8, 2016

NCCN has published updates to the NCCN Guidelines for Breast Cancer Screening and Diagnosis. These NCCN Guidelines are currently available as Version 1.2016.  “Clinical Breast Exam” was changed to “Clinical Encounter” with the footnote stating, “Clinical encounter should encompass ongoing risk assessment, risk reduction counseling, as well as a clinical breast exam.” (BSCR-1) “Consider tomosynthesis” is a...

NCCN has published updates to the NCCN Guidelines and the NCCN Drugs & Biologics Compendium (NCCN Compendium®) for Central Nervous System Cancers. These NCCN Guidelines are currently available as Version 1.2016.

Posted August 8, 2016

NCCN has published updates to the NCCN Guidelines and the NCCN Drugs & Biologics Compendium (NCCN Compendium®) for Central Nervous System Cancers. These NCCN Guidelines are currently available as Version 1.2016.   Anaplastic Gliomas (GLIO-2) The following adjuvant treatment option has been removed for 1p19q codeleted anaplastic oligodendroglioma/anaplastic oligoastrocytoma: PCV or temozolomide chemotherapy (category 2B). Glioblastoma...

NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) and NCCN Drugs & Biologics Compendium (NCCN Compendium®) for Cancer-Associated Venous Thromboembolic Disease. These NCCN Guidelines® are currently available as Version 1.2016.

Posted August 8, 2016

Venous Thromboembolism Prophylaxis VTE Prophylaxis Following Discharge and for Ambulatory Cancer Patients at Risk (VTE-2) For medical oncology patients in other outpatient settings (ie, those without multiple myeloma), the following footnote was removed: “Consider patient conversation about risks and benefits of VTE prophylaxis in patients with a Khorana score ≥3. (See Khorana Predictive Model [VTE-A...

NCCN has published updates to the NCCN Guidelines and Chemo Order Templates

Posted July 14, 2016

NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Melanoma. These NCCN Guidelines® are currently available as Version 3.2016.  Imaging recommendations were clarified, including the following: Addition of footnote “i”, specifying modalities wherever imaging is mentioned: “Chest/abdominal/pelvic CT with contrast, brain MRI with contrast, and/or FDG PET/CT. Neck CT with...

New Executive Medical Director at Florida Hospital

Posted July 13, 2016

Mark A. Socinski, MD, has been appointed Executive Medical Director of the Florida Hospital Cancer Institute. In his role, he will oversee the coordination of clinical cancer services for the Florida Hospital network. He will also be an active member of the Institute’s Thoracic Oncology Program. Dr. Socinski has spent more than 20 years in...

The FLASCO Mobile App is Here!

Posted July 10, 2016

FLASCO has launched a mobile app that provides members with an easy-to-access resource featuring clinical and drug updates, information on FLASCO events, a job board, forums, directory of members, podcasts, e-learning tools and more! The app is free and can be download in iTunes or in the Google Play Store. Some content is protected for...

Insys Therapeutics Announces FDA Approval of Syndros™

Posted July 7, 2016

Insys Therapeutics, Inc. (“Insys” or “the Company”) (INSY) today announced that the U.S. Food and Drug Administration (FDA) has approved Insys’ dronabinol oral solution, SyndrosTM, an orally administered liquid formulation of the pharmaceutical cannabinoid dronabinol, a pharmaceutical version of tetrahydrocannabinol (“THC”). Syndros is approved for use in treating anorexia associated with weight loss in patients...

NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Ovarian Cancer

Posted July 7, 2016

NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Ovarian Cancer. These NCCN Guidelines® are currently available as Version 1.2016.  ·         For patients with a suspicious palpable mass and/or symptoms, the following primary treatment option has been revised: “Patients with bulky stage III/IV who are poor surgical candidates due...

HHS Announces Physician Groups Selected for an Initiative Promoting Better Cancer Care

Posted June 29, 2016

HHS Oncology Care Model attracts almost twice the expected number of physician group practices The U.S. Department of Health and Human Services (HHS) today announced that it has selected nearly 200 physician group practices and 17 health insurance companies to participate in a care delivery model that supports and encourages higher quality and more coordinated...

Florida Physician Assistant Update:

Posted June 27, 2016

Governor Scott signed HB 375 into law on Monday, March 28, 2016.  It relates to Physician Assistants (PA) and includes the following changes to the law: At renewal, PA must acknowledge that he/she has completed a minimum of ten (10) hours continuing medical education in the specialty practice in which the PA has prescriptive privileges....

Vote Now! Dr. Lichter Nominated for Modern Healthcare’s List of 100 Most Influential People in Healthcare

Posted June 22, 2016

ASCO’s CEO, and FLASCO member, Dr. Allen Lichter, has again been nominated for Modern Healthcare magazine’s annual 100 Most Influential People in Healthcare recognition program. If you would like to vote for Dr. Lichter https://www.surveymonkey.com/r/BP3PSYP in celebration of his many contributions to ASCO and the cancer, please do so by this Friday, June 24. And feel...

Living with Prostate Cancer Event in the Villages

Posted June 15, 2016

On June 10th, FLASCO presented Living with Prostate Cancer, a patient educational breakfast program, in the Villages. We would like to thank Bayer Healthcare for the grant which funded the cost of the program and hand-out materials. This was an overwhelmingly successful event resulting in wonderful reviews from all in attendance. We would also like...

ASCO Issues Series Of Guidelines On The Management Of All Stages Of Pancreatic Cancer

Posted June 14, 2016

The American Society of Clinical Oncology (ASCO) has issued a series of guidelines on the management of all stages of” pancreatic cancer. The “guidelines on the management of potentially curable, locally advanced unresectable, and metastatic pancreatic cancer were published online…in the Journal of Clinical Oncology.”

New $10 Million Gainesville Cancer Center Delivers Comprehensive Care in Community Setting

Posted June 14, 2016

Florida Cancer Specialists & The Cancer Center at North Florida Regional Healthcare Partner to Provide Broad Range of Services Under One Roof. Florida Cancer Specialists & Research Institute announced the opening of its new location, the Gainesville Cancer Center, 6420 West Newberry Road – East Wing, Suite 100. The new state-of-the-art, comprehensive cancer facility, which...

CMS Pushes Modifier -JW Requirement to 2017

Posted June 10, 2016

CMS Pushes Modifier -JW Requirement to 2017 Source: Medicare Compliance Watch If CMS’ late April release of a change request requiring reporting of the previously optional modifier -JW (drug amount discarded/not administered to any patient) by July 1 seemed too sudden, the good news is many other providers—and the agency—agreed. Due to stakeholder concerns about...

Available Clinical Trials at UF Health Cancer Center

Posted June 10, 2016

UF Health Cancer Center has several clinical trials in process, below please find information about four trials that are currently accepting participants: ADU-CL-11 A Phase 1/2, Open-Label Safety and Efficacy Evaluation of CRS-207 in Combination With Epacadostat in Adults With Platinum-Resistant Ovarian, Fallopian, or Peritoneal Cancer. https://clinicaltrials.gov/ct2/show/NCT02575807?term=adu-cl-11&rank=1  ARGO A Phase III Randomized Placebo-Controlled Study Evaluating...

Despite stakeholder outcry, CMS launches home health prior-authorization demo

Posted June 10, 2016

Source: Modern Healthcare By Virgil Dickson Despite outcry from industry stakeholders, advocates and beneficiaries, the CMS is moving forward with a three-year demonstration in which beneficiaries from five states would need to get prior approval before they get home health services. The demonstration will launch in Florida, Illinois, Massachusetts, Michigan and Texas—states that are all tagged...

flasco logo

2016 ASCO Annual Meeting

Posted June 9, 2016

FLASCO Congratulates ASCO on a very successful and extremely educational Annual Meeting. Dr. Barry Berman, FLASCO Vice President, and Dr. Michael Diaz, FLASCO President officially represented FLASCO at the 2016 ASCO Annual Meeting.  Thank you to all of the FLASCO members and corporate members who took the time to stop by the ASCO State Affiliate...

Florida Cancer Specialists’ Research Presented at ASCO’s Annual Meeting

Posted June 9, 2016

  Florida Cancer Specialists & Research Institute (FCS) announced that there were a record 26 presentations co-authored by FCS physicians that were presented at the 2016 American Society of Clinical Oncology annual meeting, held in Chicago, IL, June 3 – 7, 2016. The ASCO annual meeting is the largest gathering of oncologists in the world....

There is still time to rate First Coast Service Options’ service.

Posted June 7, 2016

The Medicare administrative contractor (MAC) Satisfaction Indicator (MSI) is the best way to share your opinions of our service directly to CMS. This survey should only take about 10 minutes of your time and helps us understand how we can better service you. First Coast Service Options is your MAC in Florida. For a preview...

Boehringer Ingelheim launches ambitious ELUXA trial program to broadly investigate promising lung cancer compound olmutinib

Posted June 7, 2016

Comprehensive ELUXA trial program explores olmutinib (BI 1482694) as a monotherapy and in several combination studies Olmutinib will be studied in combination with the immuno-oncology therapy Keytruda®, second-generation TKI Gilotrif®, anti-angiogenic agents nintedanib and Avastin®, and Boehringer Ingelheim’s investigational IGF mAB BI 836845 Accelerated trial program underway with ELUXA 1 trial fully enrolled; additional Phase III trials...

New NCCN Imaging Appropriate Use Criteria Resources Help Assure Patients Receive Best Cancer Care Available

Posted June 2, 2016

New NCCN Imaging Appropriate Use Criteria Compendium provides a single access point for all imaging recommendations within the NCCN Guidelines FORT WASHINGTON, PA — The National Comprehensive Cancer Network® (NCCN®) has published the NCCN Imaging Appropriate Use Criteria (NCCN Imaging AUC™) to support clinical decision-making around the use of imaging in patients with cancer, helping...

ASCO Value Framework Update

Posted June 2, 2016

The American Society of Clinical Oncology (ASCO) today published an updated framework for assessing the relative value of cancer therapies that have been compared in clinical trials. The framework, published in the Journal of Clinical Oncology, defines value as a combination of clinical benefit, side effects, and improvement in patient symptoms or quality of life in...

myriad genetics

Myriad Genetics Adds Breast Cancer Prognostic Dx to Portfolio Through Sividon Acquisition

Posted June 2, 2016

Myriad Genetics announced after the close of the market Tuesday the acquisition of Sividon Diagnostics in a deal that adds a breast cancer prognostic test to Myriad’s product portfolio and enhances its competitive position in oncology diagnostics. Myriad acquired Sividon for €35 million ($39 million) upfront and up to €15 million in payments based on...

Congratulations is extended to Dr. Lucio Gordan who has accepted a term on Editorial Board of Journal of Clinical Oncology – Clinical Cancer Informatics

Posted May 19, 2016

Florida Cancer Specialists & Research Institute (FCS) is pleased to announce that Dr. Lucio Gordan, who practices at the Gainesville Cancer Center of FCS, has accepted a new term on the Editorial Board of the Journal of Clinical Oncology Clinical Cancer Informatics (JCO CCI). The Journal of Clinical Oncology, published by the American Society of...

APP Best of ASCO Travel Awards – Apply Today!

Posted May 19, 2016

CALLING ALL ONCOLOGY FLASCO MEMBER ADVANCED PRACTICED PROVIDERS: Your FLASCO Board of Directors implemented an award to assist 2 Oncology PA or NP Providers to attend the Best of ASCO® for 2016.  FLASCO will award (2)two $500 Travel Awards.  The recipients will have the opportunity to attend either the 2016 Florida Hospital Best of ASCO®...

Fellow’s ASTRO Travel Award Available -Apply Today!

Posted May 19, 2016

Oncology Focused Trainees:   Award Opportunity!  Throughout the year FLASCO offers the opportunity for FLASCO member Fellows and Residents to submit applications for Travel Awards.  If you have plans to attend the ASTRO annual meeting, please take a moment to review the attached flyer for submission requirements and directions.  You may apply for more than...

pfizer

Pfizer Awards More Than $1 Million In Metastatic Breast Cancer Research Funding Through Breast Cancer: A Story Half Told Initiative

Posted May 13, 2016

Pfizer Inc. (NYSE:PFE) today announced that it has awarded a total of more than $1 million in funding to five leading breast cancer advocacy organizations to support projects focused on metastatic breast cancer (MBC) scientific research and quality-of-life studies. The awards are part of Pfizer’s Breast Cancer: A Story Half Told initiative, aimed at uncovering...

Medivation Receives Prestigious Award From American Urological Association (AUA)

Posted May 13, 2016

SAN FRANCISCO, CA — (Marketwired) — 05/11/16 — Medivation Inc. (NASDAQ: MDVN) announced today that it is the recipient of the 2016 Health Science Award from The American Urological Association (AUA) for outstanding support of physician and patient education in prostate cancer. The Health Science Award is presented to the company that best supports the...

New Guidelines on Bladder Cancer Management: AUA/SUO

Posted May 12, 2016

Source: Medscape New joint guidelines on the management of bladder cancer issued by the American Urological Association (AUA) and the Society of Urologic Oncology (SUO) validate many long-standing practices used in the management of superficial bladder cancer but also affirm the real benefits associated with newer technologies to better visualize bladder tumors. Most notabable among...

CMS Proposes New Medicare Physician Payment System (Source: US Oncology)

Posted May 5, 2016

On April 27, the Centers for Medicare and Medicaid Services released much-anticipated proposed regulations that will govern implementation of the new Medicare physician payment system that replaces the sustainable growth rate (SGR) formula repealed by Congress last year. The new system offers physicians two pathways for Medicare payment beginning in 2019: the Merit-Based Incentive Payment...

CMS requests doc input on MACRA

Posted May 5, 2016

Source : Modern Healthcare CMS Acting Administrator Andy Slavitt struck a strongly conciliatory tone Wednesday at the second meeting of the committee created to evaluate payment models to be used in Medicare’s new reimbursement for physicians. Physician input is critical for the success of the Medicare Access and CHIP Reauthorization Act and the CMS wants...

Florida Cancer Specialists’ Physician Named FLASCO President for Second Term

Posted April 26, 2016

Thank you to Florida Cancer Specialists for recognizing Florida Society of Clinical Oncology’s President on his second term. We greatly appreciate Dr. Michael Diaz’s dedication and commitment to FLASCO, and would like to congratulate Dr. Diaz on a very successful first term. Dr. Michael Diaz Continues Leadership of Statewide Cancer Advocacy Organization Florida Cancer Specialists...

Three FLASCO Members Nominated for Leukemia & Lymphoma Society’s Man/Woman of the Year

Posted April 25, 2016

Florida Cancer Specialists & Research Institute and FLASCO are pleased to announce that Dr. Julia Cogburn, Dr. Vipul Patel andDr. Meera Iyengar have been nominated by several local Florida chapters of the Leukemia & Lymphoma Society (LLS) as Man/Woman of the Year for 2016. After an intensive nominating and vetting process, these outstanding physicians and...

Fellows Travel Awards

Posted April 25, 2016

FLASCO proudly awarded 5 Travel Awards to the following FLASCO Member Fellows. Erica Takimoto, DO, from Florida Hospital Gynecologic Oncology; Jennifer Crozier, MD, from Mayo Clinic Florida; Susmitha Apuri, MD, from Moffitt Cancer Center; Bhagirathbhai Dholaria, MBBS, from Mayo Clinic Florida; and Sharon Robertson, MD, from Moffitt Cancer Center. FLASCO supports the Oncologists of the...

FLASCO Members Visit the Hill

Posted April 25, 2016

Yesterday, FLASCO Members, Dr. Alan Marks and Dr. Morganna Freeman, along with Matthew Martello of Johnson & Johnson, participated in Biotechnology Innovation Organization’s Fly-In Legislative Day. They were able to meet with key members of Congress and their staff. They met with Representative Kathy Castor, Representative David Jolly, Representative Daniel Webster, and Representative Alan Grayson....

FDA Clarifies Compounding Rules

Posted April 25, 2016

The Food and Drug Administration issued three draft guidance documents on Friday that answer providers’ and pharmacists’ burning questions about drug compounding standards. The proposed rules clarify the amount of drugs that providers can compound without a prescription, set requirements for health system compounding pharmacies and clarify how large-scale compounding sites known as “outsourcing facilities” may be...

cancer experiment

Don’t forget: Contact Congress and ask them to Stop the Cancer Experiment!

Posted April 25, 2016

The next two weeks are critical to stopping the misguided Medicare experiment on cancer care! Make your voice heard – call, email, Tweet, and send Facebook messages to your elected officials asking them to Stop the Medicare Experiment on Cancer Care. COA has set up the CancerExperiment.com website for easy advocacy action. Share the website...

New Certificate Program for Advanced Practice Providers Launched on ASCO University

Posted April 25, 2016

Developed in partnership with professional societies that represent the full healthcare team, certificate programs for advanced practitioners who are joining oncology care settings are now available on ASCO University. These programs are designed to provide tailored education to providers with varying levels of experience, and all courses can be taken for CME, Nursing, and Pharmacy...

DISTINGUISHED SERVICE AWARD PRESENTED TO SARAH CEVALLOS: A TRUE CHAMPION AND ADVOCATE FOR PATIENT ACCESS TO CARE IN FLORIDA. 

Posted April 18, 2016

At the FLASCO Business of Oncology Summit on April 8th, on behalf of FLASCO, Thomas Marsland, MD presented an Distinguished Service Award to Sarah Cevallos, Chief Revenue Cycle Officer at Florida Cancer Specialists. Sarah was recognized for all of the time and talent she has dedicated to FLASCO’s Clinical Practice Commitee. She provides invaluable rapid updates...

COA

300+ National & State Organizations Ask Congress: Stop the CMS Drug Payment Proposal!

Posted March 17, 2016

This morning an unprecedented 313 national and state health care organizations, including FLASCO sent a letter to Congress expressing strong concern with the proposed CMS Medicare Part B Drug Payment Model. The organizations request that Congress ask CMS to withdraw the proposed rule. Click here to read the latest letter. The letter notes that the organizations believe...

2016 FMA Legislative Report

Posted March 17, 2016

During the 2016 Florida Legislative Session, which ended on Friday, March 11, the FMA kept close watch on 211 bills and a host of amendments that would have affected you and your patients. Of the total 1,638 bills and proposed constitutional amendments filed for the 60-day session, the Legislature passed 272 and has sent them...

cancer care 2016

State of Cancer Care in America: 2016

Posted March 17, 2016

The State of Cancer Care in America: 2016 report—released by the American Society of Clinical Oncology (ASCO) and published by the Journal of Oncology Practice—is the third annual report by the American Society of Clinical Oncology (ASCO) that examines trends and developments in oncology practice in the United States. The report highlights many promising cancer care developments, including...

pfizer

FDA Approves Pfizer’s Xalkori for Metastatic NSCLC

Posted March 17, 2016

On March 11, 2016, the U. S. Food and Drug Administration approved crizotinib capsules (Xalkori, Pfizer, Inc.) for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive. Crizotinib was first approved in 2011 for the treatment of patients whose tumors are anaplastic lymphoma kinase (ALK)-positive. The current approval was based...

Walgreens and LLS Create New Approach to Support Cancer Patients in their Communities

Posted March 17, 2016

The Leukemia & Lymphoma Society (LLS) and Walgreen Co. today announced the launch of an innovative collaboration designed to further advance cancer therapies and address the changing treatment model facing patients with blood and other cancers. The collaboration, between LLS and Walgreens Specialty Pharmacy, builds on the heritage of Walgreens in serving its communities, and...

FDA Approved

FDA approves first coagulation factor-albumin fusion protein to treat patients with hemophilia B

Posted March 17, 2016

The U.S. Food and Drug Administration today approved Idelvion, Coagulation Factor IX (Recombinant), Albumin Fusion Protein, for use in children and adults with Hemophilia B. Idelvion is the first coagulation factor-albumin fusion protein product to be approved, and the second Factor IX fusion protein product approved in the U.S. that is modified to last longer...

pharmacyclics

IMBRUVICA® (IBRUTINIB) APPROVED BY U.S. FDA FOR THE FIRST-LINE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA

Posted March 17, 2016

APPROVAL BASED ON DATA FROM THE PHASE 3 RESONATE™-2 TRIAL SHOWING AN 84% REDUCTION IN THE RISK OF PROGRESSION OR DEATH WITH IMBRUVICA COMPARED TO CHLORAMBUCIL FIRST FDA-APPROVED CHEMOTHERAPY-FREE TREATMENT OPTION FOR FIRST-LINE CLL PATIENTS THIS IS THE 5TH TREATMENT INDICATION FOR IMBRUVICA AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced the U.S. Food...

spectrum

FDA Grants Spectrum Pharmaceuticals Approval of EVOMELA™ (melphalan) for Injection

Posted March 17, 2016

FDA Grants Spectrum Pharmaceuticals Approval of EVOMELA™ (melphalan) for Injection EVOMELA Received FDA Approval for Two Indications: High-Dose Conditioning Treatment for Multiple Myeloma (MM) Patients Undergoing Autologous Stem Cell Transplantation (ASCT) Palliative Treatment of Patients with MM Who Cannot Take Oral Therapy EVOMELA Admixture Solution is Stable for 4 Hours at Room Temperature in Addition...

pfizer

FDA Approved New Indication for IBRANCE

Posted March 3, 2016

On February 19, 2016, the U. S. Food and Drug Administration approved palbociclib (IBRANCE Capsules, Pfizer, Inc.) in combination with fulvestrant for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy. In February 2015, FDA granted accelerated approval...

Monitoring and managing possible adverse drug reactions (ADRs) with COTELLIC + ZELBORAF1

Posted March 3, 2016

As a healthcare provider, you play an essential role in helping patients taking COTELLIC + ZELBORAF manage treatment. Genentech has created this Adverse Drug Reactions Guide as a quick reference on monitoring and managing possible serious or common ADRs.  This guide offers information on the signs and symptoms of certain possible ADRs experienced by patients...

astrazeneca

FDA Approves New Indication for FASLODEX® (fulvestrant)

Posted March 3, 2016

Approval expands use and offers additional option for women with HR+, HER2- metastatic breast cancer AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved a new indication expanding the use of FASLODEX® (fulvestrant) to include use in combination with palbociclib. The combination use is for the treatment of women with hormone...

FDA Approves New Indication for Afinitor for Progressive, Nonfunctional GI and Lung NET

Posted March 3, 2016

On February 26, 2016, the U. S. Food and Drug Administration approved everolimus (Afinitor , Novartis) for the treatment of adult patients with progressive, well-differentiated non-functional, neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin with unresectable, locally advanced or metastatic disease. Today’s approval was based on demonstration of improvement in progression-free survival (PFS) in...

Moffitt Researchers Develop a Novel Cancer Treatment Approach Based on Evolutionary Principals to Inhibit Chemo-Resistance, Prolong Progression-Free Survival

Posted March 3, 2016

Despite numerous advances in oncology since the War on Cancer began, many patients develop resistance to standard therapies and eventually relapse. Moffitt Cancer Center researchers hope to improve treatment outcomes with development of a novel therapeutic strategy, called adaptive therapy, which is based on evolutionary principals and aims to keep resistant cells in check by...

Dr. Ram Tummala Joins Florida Cancer Specialists & Research Institute

Posted March 3, 2016

Florida Cancer Specialists & Research Institute (FCSis pleased to announce that Ram Tummala, MD, has joined Florida Cancer Specialists and will be seeing patients at the FCS cancer center in The Villages East effective March 7, 2016. He will also continue to see patients at his current office in Leesburg which will add a new...

FDA Approves New Indication for Merck’s EMEND for Injection

Posted February 18, 2016

FDA Approves New Indication for Merck’s EMEND for Injection Announcement Letter Press Release Prescribing Information Patient Product Information Merck  announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for single-dose EMEND® (fosaprepitant dimeglumine) for injection, Merck’s substance P/neurokinin-1 (NK1) receptor antagonist, in combination with other antiemetic medicines,...

Puerto Rico Business of Oncology

Posted February 15, 2016

A special thanks is extended to Dr. Gerardo Colon-Otero for all of his efforts in planning and implementing a very successful Business of Oncology Summit on February 6th in San Juan, Puerto Rico.   Thanks to all who attended and participated in this event. We would like to express our sincerest gratitude to our meeting sponsors: Level 1...

FDA APPROVES EISAI’S HALAVEN® (ERIBULIN MESYLATE) INJECTION FOR THE TREATMENT OF PATIENTS WITH ADVANCED LIPOSARCOMA

Posted February 3, 2016

Eisai is pleased to announce that HALAVEN® (eribulin mesylate) Injection (0.5 mg per mL) is now approved by the US Food and Drug Administration (FDA) for the treatment of patients with unresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen.1 HALAVEN has been approved for the treatment of third-line metastatic breast cancer since...

Governor Rick Scott Declares February as Metastatic Breast Cancer Awareness Month

Posted February 1, 2016

  Governor Rick Scott Declares February as Metastatic Breast Cancer Awareness Month  TALLAHASSEE, Fla. – Metastatic breast cancer is the second leading cancer killer of women, and today Governor Rick Scott focuses attention on the complex disease by declaring February as Metastatic Breast Cancer Awareness Month in Florida. The Governor’s proclamation supports work by the Florida...

FDA Approves First Drug to Show Survival Benefit in Liposarcoma

Posted January 28, 2016

The U.S. Food and Drug Administration today approved Eisai’s Halaven (eribulin mesylate), a type of chemotherapy, for the treatment of liposarcoma (a specific type of soft tissue sarcoma) that cannot be removed by surgery (unresectable) or is advanced (metastatic). This treatment is approved for patients who received prior chemotherapy that contained an anthracycline drug. “Halaven is...

Dako, an Agilent Technologies Company, Announces Expanded FDA Approval of Complementary Diagnostic Test to Include Melanoma

Posted January 28, 2016

Dako, an Agilent Technologies Company, Announces Expanded FDA Approval of Complementary Diagnostic Test to Include Melanoma Dako, an Agilent Technologies company and a worldwide provider of cancer diagnostics, today announced that the U.S. Food and Drug Administration (FDA) has approved the expansion of the intended use of Dako PD-L1 IHC 28-8 pharmDx to include patients...

Bristol-Myers Squibb’s Opdivo (nivolumab) + Yervoy (ipilimumab) Regimen Receives Expanded FDA Approval in Unresectable or Metastatic Melanoma Across BRAF Status

Posted January 28, 2016

Opdivo + Yervoy Regimen now indicated for unresectable or metastatic melanoma patients, regardless of BRAF mutational status, based on accelerated approval1 Demonstrated significantly superior progression-free survival vs. Yervoy alone in CheckMate -067 with the first and only FDA-approved combination of immune checkpoint inhibitors1,2 FDA also expands use of Opdivo as single-agent to include previously untreated BRAF mutation-positive advanced melanoma...

abbvie logo

AbbVie, Roche’s venetoclax awarded priority review by FDA for chronic lymphocytic leukemia

Posted January 22, 2016

AbbVie and Roche’s investigational BCL-2 inhibitor venetoclax was granted priority review by the FDA for the treatment of chronic lymphocytic leukaemia (CLL) in patients, including those with p17 deletion, who received at least one prior therapy, Roche announced Tuesday. Roche chief medical officer Sandra Horning said “we look forward to working with AbbVie and health...

Ofatumumab (Arzerra Injection)

Posted January 22, 2016

On January 19, 2016, the U.S. Food and Drug Administration approved ofatumumab (Arzerra Injection, Novartis Pharmaceuticals Corporation) for extended treatment of patients who are in complete or partial response after at least two lines of therapy for recurrent or progressive chronic lymphocytic leukemia (CLL). Ofatumumab was previously approved for the treatment of previously untreated patients...

FDA Approves New Kyprolis® (Carfilzomib) Combination Therapy For The Treatment Of Patients With Relapsed Or Refractory Multiple Myeloma

Posted January 22, 2016

Originally published on CNN, here. Pivotal Head-To-Head ENDEAVOR Study Shows Kyprolis and Dexamethasone Doubled Progression-Free Survival Versus Velcade® (Bortezomib) and Dexamethasone Kyprolis Label Expansion Represents Critical Advancement for Patients With Relapsed or Refractory Multiple Myeloma, Offering New Option For Backbone Therapy Approval Expands Kyprolis Indication and Converts Monotherapy Indication to Full Approval. THOUSAND OAKS, Calif., Jan. 21,...

FLASCO and Pharmacyclics host a Successful Patient Education Event

Posted January 15, 2016

Living with CLL Orlando, FL On January 14th, FLASCO held Living with CLL Patient Education Dinner Program in Orlando, FL with support from Pharmacyclics. This was an overwhelmingly successful event with wonderful reviews from all in attendance We would like to recognize the amazing speakers that donated their time and made this program a great success. Our sincerest gratitude...

FDA Expands Label For Pembrolizumab (Keytruda® Injection)

Posted January 8, 2016

FDA Expands Label For Pembrolizumab (Keytruda® Injection, Merck Sharp & Dohme Corp) Corporate Press Release Prescribing Information Medication Guide On December 18, 2015, the U. S. Food and Drug Administration (FDA) expanded the label to include the approval of pembrolizumab (Keytruda® Injection, Merck Sharp & Dohme Corp.) for the treatment of patients with unresectable or...

J Code for KEYTRUDA® (pembrolizumab) Available

Posted January 8, 2016

 J Code for KEYTRUDA® (pembrolizumab) Available KEYTRUDA has been assigned a permanent HCPCS* code, effective January 1, 2016.1 HCPCS CODE DESCRIPTOR J9271 Injection, pembrolizumab, 1 mg   For dates of service prior to January 1, 2016, use the appropriate unspecified HCPCS code to bill for KEYTRUDA.  If you have questions about KEYTRUDA, please contact your...

Sarah Cevallos Named Chief Revenue Cycle Officer for Florida Cancer Specialists & Research Institute

Posted December 23, 2015

Cevallos to Assume Greater Leadership Role for Nation’s Largest Independent Hematology/Oncology Practice Fort Myers, FL – December 21, 2015 . . . Florida Cancer Specialists & Research Institute (FCS), the leading community oncology/hematology practice in the state, is pleased to announce that Sarah Cevallos has been named Chief Revenue Cycle Officer and is assuming a broad range of responsibilities...

Michael Essik, Inga Gonzalez and Jeff Rubin Recognized for Leadership Achievements

Posted December 23, 2015

Florida Cancer Specialists Announces Senior Management Promotions Fort Myers, FL – December 22, 2015 . . . Florida Cancer Specialists & Research Institute (FCS), the leading community oncology/hematology practice in the state, is pleased to announce the promotions of three senior leaders in the organization. Michael Essik has been promoted to Vice President of Finance;...

FDA Approves First Emergency Treatment for Overdose of Certain Types of Chemotherapy

Posted December 17, 2015

The U.S. Food and Drug Administration today approved Vistogard (uridine triacetate) for the emergency treatment of adults and children who receive an overdose of the cancer treatment fluorouracil or capecitabine, or who develop certain severe or life-threatening toxicities within four days of receiving these cancer treatments. “Treating cancer requires not only selecting which drug may...

FDA Approves New Oral Therapy to Treat ALK-Positive Lung Cancer (Genentech)

Posted December 17, 2015

Click here to read corporate press release The U.S. Food and Drug Administration today approved Alecensa (alectinib) to treat people with advanced (metastatic) ALK-positive non-small cell lung cancer (NSCLC) whose disease has worsened after, or who could not tolerate treatment with, another therapy called Xalkori (crizotinib). Lung cancer is the leading cause of cancer death...

FDA Approves Bridion to Reverse Effects of Neuromuscular Blocking Drugs Used During Surgery (Merck)

Posted December 17, 2015

The U.S. Food and Drug Administration today approved Bridion (sugammadex) injection to reverse the effects of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide, which are used during certain types of surgery in adults. Rocuronium bromide and vecuronium bromide are neuromuscular blocking drugs that cause temporary paralysis by interfering with the transmission of nerve...

teva oncology

Teva Pharmaceuticals and Eagle Pharmaceuticals Announce FDA Approval of BENDEKA™ (bendamustine hydrochloride) Injection

Posted December 11, 2015

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) and Eagle Pharmaceuticals, Inc. (Nasdaq:EGRX) today announce that the U.S. Food and Drug Administration (FDA) has approved BENDEKA™, (bendamustine hydrochloride) injection, a liquid, low-volume (50 mL) and short-time 10-minute infusion formulation of bendamustine. BENDEKA is approved for the treatment of patients with chronic lymphocytic leukemia (CLL) and for the treatment...

FDA Approves First Recombinant von Willebrand Factor to Treat Bleeding Episodes

Posted December 10, 2015

The U.S. Food and Drug Administration  approved Vonvendi, von Willebrand factor (Recombinant), for use in adults 18 years of age and older who have von Willebrand disease (VWD). Vonvendi is the first FDA-approved recombinant von Willebrand factor, and is approved for the on-demand (as needed) treatment and control of bleeding episodes in adults diagnosed with...

FDA Allows Marketing of Cooling Cap to Reduce Hair Loss During Chemotherapy

Posted December 10, 2015

U.S. Food and Drug Administration cleared for marketing in the United States the first cooling cap to reduce hair loss (alopecia) in female breast cancer patients undergoing chemotherapy. Hair loss is a common side effect of certain types of chemotherapy, commonly associated with the treatment of breast cancer. Hair may fall out entirely, gradually, in...

New HCPCS Code for CYRAMZA®

Posted December 4, 2015

Announcing the assignment of a product-specific Healthcare Common Procedure Coding System (HCPCS) code for CYRAMZA® (ramucirumab) for injection.          The new code, J9308, is defined as Injection, ramucirumab, 5 mg. This code is effective January 1, 2016. Trade Name HCPCS Code1 Strength NDC* CYRAMZA J9308 Injection, ramucirumab, 5 mg 100 mg/10 mL (10 mg/mL)   500...

FL Cancer Affiliates

FCA Adds New Medical Oncologist to Meet Growing Demand For Advanced Cancer Care Services

Posted December 2, 2015

Florida Cancer Affiliates is adding  a new medical oncologist to its staff.  Dr. Madhu K. Emani will be joining the practice November 2nd and will be caring for patients in FCA’s new Trinity treatment center. Experienced in the diagnosis and treatment of a variety of cancers, Dr. Emani has extensive expertise in both Medical Oncology...

FDA Approves Empliciti, a New Immune-Stimulating Therapy to Treat Multiple Myeloma

Posted December 2, 2015

Click here to read corporate press release  U.S. Food and Drug Administration granted approval for Empliciti (elotuzumab) in combination with two other therapies to treat people with multiple myeloma who have received one to three prior medications. Multiple myeloma is a form of blood cancer that occurs in infection-fighting plasma cells (a type of white...

Bristol-Myers Squibb’s Empliciti Gains FDA Clearance for Multiple Myeloma

Posted December 2, 2015

Click here for corporate release   The U.S. Food and Drug Administration granted approval for Empliciti (elotuzumab) in combination with two other therapies to treat people with multiple myeloma who have received one to three prior medications. Multiple myeloma is a form of blood cancer that occurs in infection-fighting plasma cells (a type of white...

FDA approves Lilly’s Portrazza to treat advanced squamous non-small cell lung cancer

Posted November 24, 2015

FDA approves Lilly’s Portrazza to treat advanced squamous non-small cell lung cancer The U.S. Food and Drug Administration today approved Portrazza (necitumumab) in combination with two forms of chemotherapy to treat patients with advanced (metastatic) squamous non-small cell lung cancer (NSCLC) who have not previously received medication specifically for treating their advanced lung cancer. Lung...

FDA approves Bristol Myers- Squibb’s Opdivo to treat Advanced Form of Kidney Cancer

Posted November 23, 2015

On November 23, 2015, the U. S. Food and Drug Administration approved nivolumab (Opdivo Injection, Bristol-Myers Squibb Company) for the treatment of advanced renal cell carcinoma in patients who have received prior anti-angiogenic therapy. The approval was based on a randomized study in which patients with advanced renal cell cancer who had received prior anti-angiogenic...

FDA approves Takeda’s Ninlaro for Multiple Myeloma

Posted November 23, 2015

On November 20, 2015, the U.S. Food and Drug Administration approved ixazomib (NINLARO, Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited) in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.  Ixazomib is the first approved oral proteasome inhibitor....

Novartis receives FDA regular approval for Tafinlar® + Mekinist® to treat aggressive form of melanoma based on long-term survival data

Posted November 23, 2015

Novartis receives FDA regular approval for Tafinlar® + Mekinist® to treat aggressive form of melanoma based on long-term survival data   The U. S. Food and Drug Administration granted accelerated approval to trametinib  and dabrafenib  for use in combination in the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K...

astrazeneca

AstraZeneca’s Tagrisso approved by FDA for advanced NSCLC

Posted November 19, 2015

On November 13, 2015, the U. S. Food and Drug Administration granted accelerated approval to osimertinib (TAGRISSO) once daily tablets, AstraZeneca Pharmaceuticals LP, for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an FDA-approved test, who have progressed on or after EGFR tyrosine...

jansen

FDA Approves Darzalex For Patients With Previously Treated Multiple Myeloma

Posted November 19, 2015

On November 16, 2015, the U.S. Food and Drug Administration granted accelerated approval to daratumumab injection (DARZALEX, Janssen Biotech, Inc.), administered as a single agent for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy, including a proteasome inhibitor (PI) and an immunomodulatory agent, or who are...

gilead

FDA Approves Gilead’s Single Tablet Regimen Genvoya® (Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Alafenamide) for Treatment of HIV-1 Infection

Posted November 12, 2015

FDA Approves Gilead’s Single Tablet Regimen Genvoya® (Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Alafenamide) for Treatment of HIV-1 Infection The U.S. Food and Drug Administration approved Genvoya (a fixed-dose combination tablet containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide) as a complete regimen for the treatment of HIV-1 infection in adults and pediatric patients 12 years of...

Brad Prechtl Named Florida Chair of CEOs Against Cancer

Posted November 12, 2015

Brad Prechtl Named Florida Chair of CEOs Against Cancer Florida Cancer Specialists’ Chief Executive Leads the Cause in the Sunshine State Florida Cancer Specialists & Research Institute (FCS) is pleased to announce that CEO Brad Prechtl has been named Chair of the Florida Chapter of CEOs Against Cancer, a program of the American Cancer Society...

FDA Approves Genentech’s Cotellic™ (Cobimetinib) in Combination With Zelboraf® (Vemurafenib) in Advanced Melanoma

Posted November 12, 2015

FDA Approves Genentech’s Cotellic™ (Cobimetinib) in Combination With Zelboraf® (Vemurafenib) in Advanced Melanoma Click here to read corporate press release The U.S. Food and Drug Administration approved Cotellic (cobimetinib) to be used in combination with vemurafenib to treat advanced melanoma that has spread to other parts of the body or can’t be removed by surgery,...

FL Cancer Affiliates

Florida Cancer Affiliates Adds New Radiation Oncologist, Enhancing the Practice’s Integrated Cancer Treatment Program

Posted November 8, 2015

Florida Cancer Affiliates (FCA) has added a new radiation oncologist to the practice. Kazumi Chino, M.D., joined the practice’s North Florida division and is providing radiation oncology services in Panama City. Dr. Chino has extensive training in the very latest state-of-the art radiation therapies and is board certified in Radiation Oncology. She treats the full...

FDA Approves IMLYGIC™ (Talimogene Laherparepvec) As First Oncolytic Viral Therapy In The US

Posted October 28, 2015

The U.S. Food and Drug Administration today approved Imlygic (talimogene laherparepvec), the first FDA-approved oncolytic virus therapy, for the treatment of melanoma lesions in the skin and lymph nodes. “Melanoma is a serious disease that can advance and spread to other parts of the body, where it becomes difficult to treat,” said Karen Midthun, M.D.,...

jansen

FDA Approval for Yondelis (Janssen) for the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma

Posted October 28, 2015

Yondelis (trabectedin) Janssen The U.S. Food and Drug Administration today approved Yondelis (trabectedin), a chemotherapy, for the treatment of specific soft tissue sarcomas (STS) – liposarcoma and leiomyosarcoma – that cannot be removed by surgery (unresectable) or is advanced (metastatic). This treatment is approved for patients who previously received chemotherapy that contained anthracycline. According to...

FDA approves new treatment for advanced pancreatic cancer

Posted October 22, 2015

The U.S. Food and Drug Administration today approved Onivyde (irinotecan liposome injection), in combination with fluorouracil and leucovorin, to treat patients with advanced (metastatic) pancreatic cancer who have been previously treated with gemcitabine-based chemotherapy. According to the National Cancer Institute, there will be 48,960 new cases of pancreatic cancer diagnosed in the U.S. in 2015,...

Sucessful Patient Advocacy Event with FLASCO and Takeda Oncology

Posted October 20, 2015

Living with Myeloma Jacksonville, FL On October 15th, FLASCO held Living with Myeloma Patient Education Dinner Program in Jacksonville, FL with support from Takeda Oncology. This was an overwhelmingly successful event with over 50 patients and caregivers in attendance. We would like to recognize the amazing speakers that donated their time and added greatly to...

rosetta genomics

Rosetta Genomics Launches BRAF Mutation Assay

Posted October 14, 2015

Rosetta Genomics Ltd. a leading developer and provider of microRNA-based and other molecular diagnostics, announces the launch of a molecular test for BRAF mutation analysis to help personalize therapy for melanoma and colon cancer patients. This newest assay will complement its broad offerings so that oncologists can optimize treatment decisions for their cancer patients. Rosetta...

FDA Expands Approved Use Of Opdivo In Advanced Lung Cancer (Bristol Myers Squibb)

Posted October 9, 2015

On October 9, 2015, the FDA approved Opdivo (nivolumab) to treat patients with advanced (metastatic) non-small cell lung cancer whose disease progressed during or after platinum-based chemotherapy. “The U.S. Food and Drug Administration today approved Opdivo (nivolumab) to treat patients with advanced (metastatic) non-small cell lung cancer whose disease progressed during or after platinum-based chemotherapy....

KEYTRUDA NOW APPROVED FOR METASTATIC SQUAMOUS AND NONSQUAMOUS NSCLC (Merck)

Posted October 9, 2015

KEYTRUDA is indicated for the treatment of patients with metastatic non–small cell lung cancer (NSCLC) whose tumors express PD-L1 as determined by an FDA-approved test with disease progression on or after platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving KEYTRUDA. This...

FDA Approved

FDA Approves Expanded Indication For Medical Device To Treat A Form Of Brain Cancer

Posted October 9, 2015

FDA approved an expanded indication for the Optune device to treat patients with newly-diagnosed glioblastoma multiforme (GBM), an aggressive form of brain cancer. It is given along with the chemotherapy drug temozolomide (TMZ) following standard treatments that include surgery, chemotherapy, and radiation therapy.  [su_button url=”http://links.govdelivery.com/track?type=click&enid=ZWFzPTEmbWFpbGluZ2lkPTIwMTUxMDA3LjQ5OTcwNzExJm1lc3NhZ2VpZD1NREItUFJELUJVTC0yMDE1MTAwNy40OTk3MDcxMSZkYXRhYmFzZWlkPTEwMDEmc2VyaWFsPTE3MjAxMTM4JmVtYWlsaWQ9RG9yb3RoeS5HcmVlbkBmbGFzY28ub3JnJnVzZXJpZD1Eb3JvdGh5LkdyZWVuQGZsYXNjby5vcmcmZmw9JmV4dHJhPU11bHRpdmFyaWF0ZUlkPSYmJg==&&&107&&&http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm465744.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery” target=”blank” style=”flat” background=”#ff002d” color=”#fafafa” size=”5″ center=”yes” icon=”icon: hand-o-right” icon_color=”#ffffff” text_shadow=”0px...

PA Week

Happy Physician Assistant Week!

Posted October 8, 2015

FLASCO wishes all PAs a Happy PA week! This marks the 50th anniversary of the PA profession. Before it was a week-long event, National PA Day was first celebrated on October 6, 1987, in honor of the 20th anniversary of the first graduating class of PAs from the Duke University PA program. October 6 is...

FCS Welcomes Vijay Patel, MD

Posted October 1, 2015

FCS Welcomes Visjay Patel, MD Florida Cancer Specialists & Research Institute (FCS), the leading community oncology/hematology practice in the state, is pleased to announce that Vijay Patel, MD, has joined Florida Cancer Specialists and will be seeing patients at the FCS cancer center in Gainesville at 1147 NW 64th Terrace.  Dr. Patel began practicing medical...

Bristol-Myers Squibb Receives Approval from the U.S. Food and Drug Administration for the Opdivo (nivolumab) + Yervoy (ipilimumab) Regimen in BRAF V600 Wild-Type Unresectable or Metastatic Melanoma

Posted October 1, 2015

Bristol-Myers Squibb Company announced that the U.S. Food and Drug Administration (FDA) approved Opdivo (nivolumab) in combination with Yervoy (ipilimumab), for the treatment of patients with BRAF V600 wild-type unresectable or metastatic melanoma. Read Corporate Press Release FDA Information: U. S. Food and Drug Administration granted accelerated approval to nivolumab (Opdivo Injection, Bristol-Myers Squibb Company) in...

AdvaMed CEO Ubl to lead PhRMA

Posted October 1, 2015

AdvaMed CEO Ubl to lead PhRMA Source: Modern Healthcare By Adam Rubenfire    September 25, 2015 Stephen Ubl, the lead lobbyist for the medical device industry, has been named president and CEO of the Pharmaceutical Research and Manufacturers of America. Ubl, 46, has led the Advanced Medical Technology Association, or AdvaMed, a medical device trade group,...

Merck and Pfizer Announce FDA Orphan Drug Designation for Investigational Immunotherapy Avelumab in Merkel Cell Carcinoma

Posted October 1, 2015

(BUSINESS WIRE)–Merck and Pfizer announced that the US Food and Drug Administration (FDA) has granted orphan drug designation for the investigational cancer immunotherapy avelumab* for the treatment of Merkel cell carcinoma (MCC), a rare and aggressive type of skin cancer.1,2 Each year, there are approximately 1,500 new cases of MCC diagnosed in the US.3 “We...

Welcome to ICD-10

Posted October 1, 2015

Welcome to ICD-10 CMS BLOG http://blog.cms.gov/2015/10/01/welcome-to-icd-10/ By Sean Cavanaugh, Deputy Administrator and Director, Center for Medicare Today, the U.S. health care system moves to the International Classification of Diseases, 10th Revision – ICD-10. We’ve tested and retested our systems in anticipation of this day, and we’re ready to accept properly coded ICD-10 claims. The change...

Bipartisan Lawmakers Send Letters to CMS Opposing Proposed Cuts to Radiation Therapy

Posted October 1, 2015

Bipartisan Lawmakers Send Letters to CMS Opposing Proposed Cuts to Radiation Therapy (Source:  US Oncology) This week 228 bipartisan lawmakers in Congress sent three letters to the Centers for Medicare & Medicaid Services (CMS) asking the agency to reconsider proposed cuts to radiation oncology recommended in its 2016 Physician Fee Schedule (PFS) Proposed Rule. In...

Moffitt Cancer Center and Bristol-Myers Squibb Enter Into a Collaboration Agreement as Part of U.S. Immuno-Oncology Rare Population Malignancy Program

Posted September 30, 2015

Moffitt Cancer Center and Bristol-Myers Squibb   Enter Into a Collaboration Agreement as Part of U.S. Immuno-Oncology Rare Population Malignancy Program   NEW YORK & TAMPA, Fla., Sep 25, 2015 (BUSINESS WIRE) — Bristol-Myers Squibb Company  and Moffitt Cancer Center today announced that they have entered into a collaboration agreement as part of Bristol-Myers Squibb’s Immuno-Oncology...

Courtesy Calls from First Coast Service Options

Posted September 30, 2015

Courtesy Calls from First Coast Service Options First Coast has a new team (CERT Clinical Nurse Educators) making daily calls to providers across JN regarding CERT claims that have been audited by the CERT contractor and assessed with an error.  Our goal in making one-to-one education calls is to provide outreach regarding specific education related...

CMS Proposes New Medicare Clinical Diagnostic Laboratory Tests Fee Schedule

Posted September 30, 2015

CMS Proposes New Medicare Clinical Diagnostic Laboratory Tests Fee Schedule Proposed initiative would begin data collection process to set new payment rates   WASHINGTON (September 25, 2015) – The Centers for Medicare & Medicaid Services (CMS) today announced its next step in implementing the Protecting Access to Medicare Act of 2014 (PAMA), requiring clinical laboratories...

taiho oncology

U.S. Food and Drug Administration approved LONSURF® (trifluridine and tipiracil) tablets

Posted September 30, 2015

On September 22, 2015, the U.S. Food and Drug Administration approved LONSURF® (trifluridine and tipiracil) tablets. LONSURF is a combination of trifluridine, a nucleoside metabolic inhibitor, and tipiracil, a thymidine phosphorylase inhibitor, indicated for the treatment of patients with metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF...

Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial

Posted September 24, 2015

Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial   The Lancet Oncology has recently published the overall survival (OS) data from a head-to-head Phase III clinical trial. The study evaluated a lung cancer treatment as a potential option for patients with...

spohnc

Support for People With Oral and Head and Neck Cancer

Posted September 24, 2015

“Find a Clinical Trial for Oral, Head and Neck Cancer” Call toll-free 844-432-3888 (Mon-Fri, 9 am -5 pm ET) SPOHNC is pleased to introduce EmergingMed’s Clinical Trial Navigation Service. We want you to be aware of all of your treatment options. SPOHNC has partnered with EmergingMed to offer you a way to take action. The...

taiho oncology

FDA Approves New Oral Medication to Treat Patients with Advanced Colorectal Cancer

Posted September 23, 2015

FDA Approves New Oral Medication to Treat Patients with Advanced Colorectal Cancer The U.S. Food and Drug Administration today approved Taiho Oncology’s Lonsurf (a pill that combines two drugs, trifluridine and tipiracil) for patients with an advanced form of colorectal cancer who are no longer responding to other therapies. “The past decade has brought a new...

Health First Acquires Space Coast Cancer Centers

Posted September 21, 2015

Health First Acquires Space Coast Cancer Centers A unit of Health First on Friday completed its acquisition of Space Coast Cancer Center, which had facilities in Titusville, Viera and Merritt Island. Former FLASCO President and Current FLASCO Board Member, Dr. Richard Levine, who founded and was president of the Space Coast Cancer Center, said the facilities...

Conquer Cancer Foundation

Six Words Parents Hope They Never Have to Hear

Posted September 18, 2015

“Your child needs a heart transplant.” Dr. Kasey Leger of Seattle Children’s Hospital – one of our most promising researchers – is working toward the day when parents of children who survived cancer will never have to hear those words. Can you imagine how you would feel after watching your child conquer cancer after enduring...

COA

New Study Reveals 340B Program Significantly Larger Than Previously Understood

Posted September 15, 2015

A new study released today from the Community Oncology Alliance (COA) finds that the 340B drug discount program is significantly larger than previous estimates have shown. Much of the growth is concentrated in oncology drugs for which 340B hospitals cost Medicare and beneficiaries more than community oncology clinics. [su_button url=”http://app.streamsend.com/c/24877027/900393/vmfceBi/SWYY?redirect_to=http%3A%2F%2Fwww.thestreet.com%2Fstory%2F13288335%2F1%2Fnew-study-reveals-340b-program-significantly-larger-than-previously-understood.html” target=”blank” style=”flat” background=”#f70032″ color=”#ffffff” size=”5″...

16th World Lung Cancer Congress

Oral Presentation at The 16th World Lung Cancer Congress

Posted September 15, 2015

Dear coauthors our research project regarding genetic analysis of tumors in lung cancer patients with Hispanic origin was not only approved and selected to be presented as ORAL presentation at the 16th World Lung Cancer Congress where I had the honor to present on your behalf; but also it was chosen among more than 3,000...

ADCETRIS® (brentuximab vedotin) NEW INDICATION

Posted September 15, 2015

ADCETRIS® (brentuximab vedotin)  NEW INDICATION   Dear Healthcare Professional: Seattle Genetics is pleased to announce FDA approval for use of ADCETRIS® (brentuximab vedotin) as post-autologous hematopoietic stem cell transplantation (auto-HSCT) consolidation treatment for patients with classical Hodgkin lymphoma (HL) at high risk of relapse or progression. The FDA decision was based on the positive results...

Florida Cancer Affiliates Names New Executive Director

Posted September 10, 2015

Florida Cancer Affiliates Names New Executive Director John E. Brown will lead Tampa, North Florida, and Ocala facilities, bringing extensive healthcare management experience to the practice New Port Richey, Fla. (September 10,  2015) – Florida Cancer Affiliates (FCA), a leading provider of advanced cancer care services in Florida and a practice in The US Oncology Network, has...

Boehringer Ingelheim – Biomarker Testing

Posted September 4, 2015

Boehringer Ingelheim has a website that provides information to assist with biomarker testing on Advanced Non Small Cell Lung Cancer.  Explore “Let’s Test” for a wealth of resources.  In the age of personalized medicine, oncologists can routinely order biomarker tests for their patients with advanced NSCLC—and use the results to consider more tailored treatment. Treatment decisions...

Posted September 2, 2015

FCSO Promotes Electronic Remittance Advice The First Coast Service Options, Inc.,. Provider Outreach and Education department is working to promote Electronic Remittance Advice (ERA) to those providers still receiving paper remittances through regular mail. FCSO has been performing focused education by reaching out to those providers that still receiving paper remittances and offering education and...

Ferdy Santiago, MD Joins Florida Cancer Affiliates

Posted September 2, 2015

Florida Cancer Affiliates Expands Patient Access to Cutting-Edge Care with the Addition of Ferdy Santiago, MD Florida Cancer Affiliates (FCA), a community-based radiation oncology, medical oncology, and hematology practice announces that Ferdy Santiago, MD, has joined its practice and has begun seeing patients at its two centers at 8570 Granite Court, Fort Myers, Florida 33908...

Hematology and Oncology Consultants, PA Joins Florida Cancer Specialists & Research Institute

Posted September 2, 2015

Hematology and Oncology Consultants, PA Joins Florida Cancer Specialists & Research Institute Florida Cancer Specialists and Research Institute  is pleased to announce that Hematology and Oncology Consultants, PA (HOC) is joining the practice, effective September 1, 2015. The alliance with HOC will add two clinical sites to the Florida Cancer Specialists’ network, extending services in...

tesaro

FDA Approves Varubi (rolapitant) Treatment for Nausea and Vomiting from Chemotherapy

Posted September 2, 2015

FDA Approves Varubi (rolapitant)  Treatment for Nausea and Vomiting from Chemotherapy The U.S. Food and Drug Administration approved Varubi (rolapitant) to prevent delayed phase chemotherapy-induced nausea and vomiting (emesis). Varubi is approved in adults in combination with other drugs (antiemetic agents) that prevent nausea and vomiting associated with initial and repeat courses of vomit-inducing (emetogenic...

Join the Effort to Stop Medicare Cuts to Radiation Oncology

Posted August 27, 2015

Join the Effort to Stop Medicare Cuts to Radiation Oncology  Contact Your Members of Congress Today! In its 2016 Physician Fee Schedule Proposed Rule, CMS is proposing overall Medicare cuts of three percent to radiation oncology services, and an even deeper six percent Medicare cut to freestanding radiation therapy centers.   The proposed rule most...

Moffitt Cancer Center Researchers Develop Genetic Test that Predicts which Pancreatic Cancer Patients will Benefit from Surgery

Posted August 26, 2015

Moffitt Cancer Center Researchers Develop Genetic Test that Predicts which  Pancreatic Cancer Patients will Benefit from Surgery Pancreatic cancer, a highly lethal malignancy, is the fourth most common cause of cancer-related mortality in the United States.  Approximately 25 percent of patients with early cancers undergo potential curative treatment with surgery and chemotherapy. Unfortunately, only about...

NCCN Publishes New Patient Education Resources for Kidney Cancer

Posted August 26, 2015

NCCN Publishes New Patient Education Resources for Kidney Cancer NCCN has published the NCCN Guidelines for Patients® and NCCN Quick Guide™ for Kidney Cancer, the newest addition to the library of NCCN Guidelines for Patients. Kidney Cancer is among the 10 most diagnosed cancers in both men and women in the United States, and it...

FDA approves Promacta (eltrombopag) to Treat Low Blood Platelet Count in Pediatric Patients

Posted August 24, 2015

FDA approves Promacta (eltrombopag) to Treat Low Blood Platelet Count in Pediatric Patients The U.S. Food and Drug Administration today approved Promacta (eltrombopag) to treat low blood platelet count in pediatric patients – ages one year and older – with a rare blood disorder called chronic immune thrombocytopenic purpura (ITP). Promacta can be used in...

PEREGRINE INSTITUTE

Introducing The Peregrine Institute

Posted August 18, 2015

Grand Opening on September 4, 2015 Dr. Jose Sarria has been the Chief of the Pain Medicine Service at Moffitt Cancer Center in Tampa since 2005. During this time, he became aware of a pressing need for  dedicated pain and symptom management of cancer patients and particularly of cancer survivors, a growing population that frequently...

Seattle Genetics Announces FDA Regular Approval of ADCETRIS® (Brentuximab Vedotin) for Classical Hodgkin Lymphoma Patients at High Risk of Relapse or Progression as Post-Autologous Hematopoietic Stem Cell Transplantation Consolidation

Posted August 18, 2015

[su_list icon=”icon: check” icon_color=”#1243fe”] FDA Approval Based on the Phase 3 AETHERA Clinical Trial Results- AETHERA Trial Also Converts Prior Accelerated Approval to Regular Approval in Treatment of Classical Hodgkin Lymphoma Patients who Fail Autologous Hematopoietic Transplantation or who Fail at Least Two Prior Multi-Agent Chemotherapy Regimens and are Not Autologous Hematopoietic Transplantation Candidates Label...

Dr. Steven B. Newman Joins Florida Cancer Specialists & Research Institute

Posted August 18, 2015

Florida Cancer Specialists & Research Institute (FCS),  is pleased to announce that Steven B. Newman, MD, has joined Florida Cancer Specialists and will be seeing patients at the FCS cancer center at Napa Ridge, located at 6360 Pine Ridge Road – Suite 201, Naples, FL 34119.Dr. Steven B. Newman has over 30 years experience as...

FLASCO Wants to Hear Your Step Therapy Story

Posted August 13, 2015

FLASCO Wants To Hear Your Step Therapy Story FLASCO is working with other health care organizations to encourage Florida lawmakers to address the negative impact of Step Therapy policies. We are currently looking for stories about barriers and challenges to navigating Step Therapy and fail-first policies to share with the media. If you have any...

Home Health Physician Certification Letter

Posted August 11, 2015

Home Health Physician Certification Letter 05 06 2015 CMDs (Source: Contractor Medical Directors, Home Health/Hospice Medicare Contractors) Medicare has changed the physician documentation requirements for certification of home health care for dates of service effective January 1, 2015. While clinicians still need to certify benefit eligibility and a face to face encounter is still required,...

myriad genetics

Myriad’s myPlan® Lung Cancer

Posted August 6, 2015

 Myriad’s myPlan® Lung Cancer Myriad’s myPlan® Lung Cancer is a new RNA 46-gene expression signature based on cell cycle progression (CCP) genes —the genes that regulate cell division. myPlan Lung Cancer measures the expression levels of specific genes in combination with pathological stage to predict the 5-year risk of lung cancer death in patients with...

Florida Department of Health hosts Cancer Research Symposium

Posted August 5, 2015

The Florida Department of Health is hosting a Cancer Research Symposium for the general public, designed to highlight and explain research funded through the Bankhead-Coley Cancer Research Program and the James and Esther King Biomedical Research Program. When: Friday, September 18, 2015 Where: University of Central Florida – College of Medicine, Orlando, Florida Click here to...

AKYNZEO® (netupitant/palonosetron) – FLASCO News Flash

Posted August 5, 2015

AKYNZEO® (netupitant/palonosetron) Florida Society of Clinical Oncology (FLASCO) News Flash In 2014, Eisai launched AKYNZEO (netupitant/palonosetron), a dual-action, single-dose oral antiemetic for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy. AKYNZEO is an oral fixed combination of...

Dr. Rakesh Rohatgi Merges His Practice With FCS

Posted August 4, 2015

Dr. Rakesh Rohatgi Merges His Practice With Florida Cancer Specialists & Research Institute Tri-County Hematology & Oncology Joins FCS    Fort Myers, FL –  August 3, 2015 . . .Florida Cancer Specialists & Research Institute , is pleased to announce that Rakesh Rohatgi, MD, is merging his practice (Tri-County Hematology & Oncology) with Florida Cancer Specialists...

Dr. Shilpa Oberoi Joins Florida Cancer Specialists & Research Institute

Posted August 4, 2015

 Dr. Shilpa Oberoi Joins Florida Cancer Specialists & Research Institute in Ocala Cancer Center Florida Cancer Specialists & Research Institute,  is pleased to announce that Shilpa Oberoi, MD, has joined Florida Cancer Specialists and will be seeing patients at the FCS cancer center in Ocala, located at 1630 SE 18th Street, Suite 602, Ocala, FL 34471.Dr....

Florida Cancer Affiliates Acquires Radiation Oncology Facility in Panama City

Posted August 4, 2015

Florida Cancer Affiliates Acquires Radiation Oncology Facility in Panama City   Panama City, Fla. (August 4, 2015) – Florida Cancer Affiliates (FCA), a practice in The US Oncology Network, acquired a radiation oncology facility in Panama City. The acquisition allows the medical oncologists of FCA to offer a full range of both medical oncology and...

Univita Termination with All Statewide Medicaid Managed Care Plans and UnitedHealthcare Subcontract

Posted July 30, 2015

Univita Termination with All Statewide Medicaid Managed Care Plans The Statewide Medicaid Managed Care (SMMC) plans will no longer contract with Univita for home health, durable medical equipment (DME) or intravenous therapy for their Medicaid members. Providers should continue providing services to enrollees during the transition period for any services that were previously authorized or...

DK Pierce chosen as one of 2015 Indiana Companies to Watch

Posted July 29, 2015

Denise Pierce has moderated and help plan many of FLASCO’s conferences.  She is a huge asset to FLASCO in countless ways. Congratulations Denise you deserve it!!   DK Pierce chosen as one of 2015 Indiana Companies to Watch 2015 has been quite a milestone year for DK Pierce & Associates (DK Pierce), and I wanted...

FLASCO Member Dr. Napoleon Santos joins FCS

Posted July 29, 2015

FLASCO Member, Dr. Napoleon Santos joins Florida Cancer Specialists   Florida Cancer Specialists & Research Institute and FLASCO are pleased to announce that Napoleon Santos, DO, has joined Florida Cancer Specialists and will be seeing patients at the FCS cancer center in West Palm Beach, located at 1309 N. Flagler Drive, West Palm Beach, FL 33401....

Sonidegib (Odomzo Capsules) Approved by FDA

Posted July 27, 2015

Sonidegib (Odomzo Capsules) Approved by FDA (Novartis Pharmaceuticals Corporation) FDA approved sonidegib (Odomzo Capsules, Novartis Pharmaceuticals Corporation) for the treatment of patients with locally advanced basal cell carcinoma (BCC) that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy. July 24, 2015. More Information: http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm455865.htm

Carfilzomib (Kyprolis) Approved by FDA

Posted July 27, 2015

Carfilzomib (Kyprolis) Approved by FDA (Onyx Pharmaceuticals, Inc., an Amgen Subsidiary) On July 24, 2015, the U.S. Food and Drug Administration approved a new indication for Kyprolis® (carfilzomib) for injection.1   KYPROLIS can now be used in combination with lenalidomide and dexamethasone for the treatment of patients with relapsed multiple myeloma who have received one to...

HCFA Physician Chemotherapy Claims Processing Errors and Recovery

Posted July 24, 2015

UnitedHealthcare discovered a programming error in their claims system that has been incorrectly denying prior authorized chemotherapy treatments.  This notice was placed on the company’s portal on July 23, 2015. HCFA Physician Chemotherapy Claims Processing Errors and Recovery UnitedHealthcare launched its Injectable Outpatient Chemotherapy Prior Authorization program requirement effective June 1, 2015 to improve the...

Afatinib versus Erlotinib as Second-line Treatment Phase III Clinical Trial Update

Posted July 23, 2015

Afatinib versus Erlotinib as Second-line Treatment Phase III Clinical Trial Update Boehringer Ingelheim Pharmaceuticals, Inc. would like to share the overall survival (OS) data from a head-to-head Phase III clinical trial that was recently published in The Lancet Oncology. The study evaluated the company’s lung cancer treatment as a potential option for patients with advanced...

FAPA Capitol Hill Days

Posted July 22, 2015

YOU’RE INVITED TO MAKE A DIFFERENCE! Join the Florida Academy of Physician Assistants for our Capitol Hill Days this November 2-4, 2015, at the Four Points by Sheraton in Tallahassee, Florida!  Because the 2016 Legislative Session will begin two months earlier than usual, FAPA has scheduled Capitol Hill Days earlier, too. Register by September 1,...

FL Cancer Affiliates

Florida Cancer Affiliates to Host Stress Reduction Support Group Meetings

Posted July 22, 2015

Florida Cancer Affiliates to Host Stress Reduction Support Group Meetings Trinity, Florida (July 22, 2015) — Florida Cancer Affiliates (FCA), a community-based medical oncology, hematology and radiation oncology practice, announces that its new Trinity center will host a stress reduction support group meeting once a month on a Wednesday from 6 pm to 7:30 pm...

Genentech’s Investigational Immunotherapy Atezolizumab Study Update

Posted July 22, 2015

In a Pivotal Study, Genentech’s Investigational Immunotherapy Atezolizumab Shrank Tumors in People With a Specific Type of Bladder Cancer Results showed that high levels of PD-L1 expression were associated with greater responses to atezolizumab Genentech will discuss results with the U.S. Food and Drug Administration (FDA) as part of atezolizumab’s Breakthrough Therapy Designation in bladder...

Genentech CoPay Program Update

Posted July 20, 2015

Genentech CoPay Program Update Effective June 30th the Genentech CoPay Program made the following changes: Genentech has a co-pay card program for eligible patients with private insurance taking Genentech cancer medicines. The co-pay program helps to cover eligible patients’ monthly costs so patients pay $25 co-pay per medicine.  The card covers up to $25,000 per...

The importance of nurses in cancer care

Posted July 20, 2015

The importance of nurses in cancer care The Lancet Oncology Volume 16, No. 7, p737, July 2015 In early June, 2015, it became apparent that the UK National Health Service (NHS) had spent £3·3 billion on temporary nurses’ agency fees in the past financial year. Health Secretary Jeremy Hunt ascribed this increased use of agency...

astrazeneca

FDA Approved AstraZeneca’s Gefitinib (Iressa)

Posted July 13, 2015

AstraZeneca recently received approval from the Food and Drug Administration for IRESSA® (gefitinib) as a first-line treatment in patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test. IRESSA is approved in 91 countries...

Oncofertility Consortium

Posted July 8, 2015

The Oncofertility Consortium® is a national, interdisciplinary initiative designed to explore the reproductive future of cancer survivors. Survival rates among young cancer patients have steadily increased over the past four decades in part because of the development of more effective cancer treatments. Today, both women and men can look forward to life after cancer, yet...

Livestrong Fertility

Posted July 8, 2015

Since 1997, the LIVESTRONG Society has been working to improve the lives of people affected by cancer. They started as a small group trying to raise money to fight the disease. As cancer has quietly become the world’s leading cause of death, their work has expanded and now reaches every corner of the globe. One...

Physician Resources NEW T-cell Lymphoma Resource Center Now Available Through QuantiaMD

Posted July 8, 2015

This educational resource is provided by Celgene and designed to provide an understanding of the classification, diagnosis of subtypes, and disease management of peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL).  Physicians can choose to “follow” the resource center and receive alerts when new information is added.  To visit the T-cell Lymphoma Resource Center,...

Breast Cancer Funding Reinstated

Posted June 16, 2015

The Florida Breast Cancer Foundation would like to share the following good news!! In case you haven’t heard the good news, we are thrilled to announce that last night, we were not only able to restore the current year funding of $1.8 million, but also INCREASED it, bringing funding for the program to an all-time...

Congratulations Dr. Mohammad Jahanzeb!

Posted June 15, 2015

Mohammad Jahanzeb, M.D., Medical Director of Sylvester Comprehensive Cancer Center at Deerfield Beach, has been appointed Chair-Elect of the American Society of Clinical Oncology’s Quality Oncology Practice Initiative (QOPI®) Steering Group Committee. Jahanzeb, professor of medicine, has been instrumental in the development of QOPI since its inception in 2002. He has served as a member...

2015 FLASCO Spring Session

Posted April 22, 2015

April 10th and 11th FLASCO held its Annual Meeting and Spring Session in Orlando at the Marriott World Center.  We would like to express a special thanks to the FLASCO Program Committee for all of their hard work in planning the Spring General Session.  There were great speakers with informative and captivating presentations. Thank you to...

FLASCO Business of Oncology

Posted April 22, 2015

A special thanks is extended to Dr. Thomas Marsland for all of his efforts in planning and implementing a very successful Business of Oncology Conference on April 10th.  We had 240 attendees at this great conference. Thanks to all who attended and participated in this event. Additionally, a special thanks is extended to Denise Pierce,...

biodesix

VeriStrat®

Posted March 26, 2015

VeriStrat®   Lung Cancer Journal: VeriStrat Proteomic Test Improves Overall Survival and Decreases Medical Costs for Patients with Advanced NSCLC BOULDER, Colo.—March 24, 2015— Biodesix, Inc. today announced the publication in the journal Lung Cancer of a pivotal paper demonstrating the economic implications to the US healthcare system of using VeriStrat® in guiding treatment of...

Mayo Clinic HemOnc Reviews 2015 – Call for Submissions

Posted March 10, 2015

Mayo Clinic Hem/Onc Reviews 2015   Mayo Clinic would like to  invite Fellows to submit a research abstract for the 16th Annual Mayo Clinic Hematology/Oncology Fellows’ Research Symposium as part of the 25th Annual Mayo Clinic Hematology/Oncology Reviews scheduled for July 29 – August 1, 2015 at The Ritz Carlton in Amelia Island, FL. Fellows are invited to submit...

FLASCO Foundation Inc. Holds It’s First Patient Advocacy Program!

Posted February 25, 2015

The Goal of the FLASCO Foundation, Inc., Outreach program is to bring together cancer patients, cancer survivors, caregivers, oncology experts and corporate supporters together to learn and exchange information on various types of cancer. This project was the dream of Past President Gerald Robbins, MD. This was one of his main initiatives and it was...

FLASCO BUSINESS OF ONCOLOGY & SPRING SESSION

Posted February 3, 2015

Friday, April 10 join us at the Marriott Orlando World Center to learn the art of navigating the increasingly complex map of clinical practice. Hear how each of the stakeholders are approaching the current terrain and what they are doing to prepare for the next big curve in the road. Plan to stay to hear...

Florida Cancer Specialists New Location in Hudson

Posted January 16, 2015

Florida Cancer Specialists & Research Institute Announces New Office Location in Hudson, FL Nation’s Largest Independent Oncology/Hematology Practice Relocating Office in Pasco County Hudson, FL – January 15, 2015 . . . . Florida Cancer Specialists & Research Institute (FCS), the largest independent medical oncology/hematology practice in the United States, announced a new clinical location in Hudson,...

Education for Young Women re: Cancer Risks

Posted January 13, 2015

Campaign to Educate Young Women About Breast Cancer Risks Reauthorized by House WASHINGTON – The Breast Health Education and Awareness Requires Learning Young Act, or the EARLY Act, was reauthorized for five years today by the House of Representatives. H.R. 5185 was introduced by Rep. Debbie Wasserman Schultz (D-Fla.) and Rep. Renee Ellmers (R-N.C.).  Authored...

Medical Student Scholarships – Available

Posted January 2, 2015

The Foundation of Collier County Medical Society has introduced a new scholarship award for medical students who are Florida residents and have demonstrated excellence in community service. April Donahue, Executive Director of Collier County Medical Society, would be very grateful if you could forward this information to medical students that you come into contact with. The...

Annie Appleseed Promotes Health Living

Posted January 2, 2015

Support for Partnerships to Promote Healthy Living The BUILD Health Challenge is a national program designed to support community collaborations that are working to give everyone a fair chance to be healthy. Specifically, the Challenge provides awards to strengthen partnerships among hospitals, nonprofit organizations, local health departments, and other community organizations to improve the health of...

Dr. Wasif Riaz Joins Florida Cancer Specialists & Research Institute

Posted December 5, 2014

  Dr. Wasif Riaz Joins Florida Cancer Specialists & Research Institute Nation’s Largest Independent Hematology/Oncology Practice Welcomes  New Physician to Sebring Office Fort Myers, FL – December 3, 2014 . . . . Florida Cancer Specialists & Research Institute (FCS), the largest independent medical oncology/hematology practice in the United States, is pleased to announce that Wasif Riaz, MD,...

CMS Proposes New Risk Model Under Medicare Shared Savings Program

Posted December 5, 2014

CMS releases new proposal to improve Accountable Care Organizations Shared Savings Program Proposed Rule reflects focus on primary care and improved incentives for participation, quality, and efficiency The Centers for Medicare & Medicaid Services (CMS) today released a proposal to strengthen the Shared Savings Program for Accountable Care Organizations (ACOs) through a greater emphasis on...

Drs. Karin Bigman, Eric Harris and Mudussara Khan Join Florida Cancer Specialists & Research Institute

Posted December 5, 2014

  Drs. Karin Bigman, Eric Harris and Mudussara Khan Join Florida Cancer Specialists & Research Institute Nation’s Largest Independent Oncology/Hematology Practice Adds New Offices in Daytona and Ormond Beach Fort Myers, FL – December 4, 2014 . . . . Florida Cancer Specialists & Research Institute (FCS), the leading community oncology/hematology practice in Florida, is pleased...

Facing a medical audit? FMA has built a toolkit!

Posted December 5, 2014

The link below will take you to the FMA website. Facing a medical audit? Use this toolkit as your guide The Physicians Advocacy Institute (PAI) and the American College of Emergency Physicians (ACEP) have published a Toolkit for Physicians Facing Medical Audits. The FMA has partnered with PAI and ACEP to disseminate this toolkit, which...

Get the latest on the Affordable Care Act

Posted December 5, 2014

Clicking below will take you to the FMA website who will share the latest on the Affordable Care Act. Update on the Affordable Care Act Click here for the latest Affordable Care Act update from FMA Director of Payment Advocacy Jarrod Fowler, including an analysis of a recent Government Accountability Office report on competition and...

Florida Cancer Specialists & Research Institute Announces $2.5 Million Expansion of Corporate Headquarters

Posted December 5, 2014

Florida Cancer Specialists & Research Institute Announces  $2.5 Million Expansion of Corporate Headquarters Nation’s Largest Independent Oncology/Hematology Practice  Holds Groundbreaking Ceremony to Accommodate Growth Fort Myers, FL – December 4, 2014 . . . . Florida Cancer Specialists & Research Institute (FCS), the largest independent medical oncology/hematology practice in the United States, announced a $2.5 million expansion...

Who’s Online

There are no users currently online